

Subject index

Numbers following entries are abstract numbers.

- ABC transporters, 5030, 6021
 ABCB1 Gene SNP, 5156
 ABCC2, 1105
 Abdomen neoplasms, 2062
 Abdominoperineal excision, 6012
 Abdominoperineal resection, 6084
 Abiraterone, 7000, 7001, 7015, 7055, 7056, 7057, 7058
 Ablation, 2502
 Accelerated partial breast irradiation, 5125
 Accelerated radiotherapy, 8567
 Acidosis, 1041
 Acoustic neuroma, 8700
 Action plan, 4257
 Acute lymphoblastic leukaemia (ALL), 4106, 4109, 4113, 4119, 4128, 4217, 9203, 9224, 9237, 9239
 Acute mucositis, 8568
 Acute myeloid leukaemia, 1014, 1213
 Acute toxicity, 8551
 Adaptive radiotherapy, 2013, 2022, 2059
 Adaptor protein, 1058
 Adenocarcinoma, 1431, 8014, 8530, 9011, 9018, 9152
 Adenoid cystic carcinoma, 8502
 Adenosine nucleotides, 1015
 Adenosquamous carcinoma, 8539
 Adherence, 135, 242, 4217
 Adherence of patient, 243
 Adipokines, 1091, 4013
 Adipose tissue, 7158
 Adjuvant chemoradiation, 8532
 Adjuvant chemoradiotherapy, 6037, 7124
 Adjuvant chemotherapy, 4009, 4020, 5018, 5178, 6075, 6116, 6117, 6505, 6521, 6570, 6578, 7129, 9008
 Adjuvant endocrine therapy, 5169
 Adjuvant FEC-D, 5154
 Adjuvant systemic therapy, 315, 5161
 Adjuvant therapy, 3632, 5019, 5112, 5157, 6108, 6549, 7122, 7123, 7164
 Administrative claims database, 6162
 Adolescents, 4121, 4167, 9224
 Adoptive T cell therapy, 1111
 Adult long term survivors, 22
 Advanced ampullary carcinoma, 6574
 Advanced basal cell carcinoma, 9331
 Advanced breast cancer, 5032, 5063, 5089
 Advanced cancer, 295, 323
 Advanced colorectal cancer, 6114
 Advanced disease, 7110, 7146
 Advanced external irradiation techniques, 297
 Advanced gastric cancer, 6592, 6593, 6600, 6631
 Advanced head and neck cancer, 8579
 Advanced kidney cancer, 7137, 7147, 7148
 Advanced NSCLC, 1443, 9000, 9019, 9074, 9093, 9121, 9122
 Advanced nursing roles, 4150
 Advanced practice, 4182, 4183
 Advanced stage, 9110
 Adverse drug events, 4017
 Adverse events, 3030, 3047, 4266, 5158, 7034, 7133, 7162, 9056
 AEG-1, 9004, 9142
 Afatinib, 1204, 1417, 9007
 Ag colloidal nanoparticles, 9327
 Age, 223
 Ageing, 4029
 Aggressive fibromatosis, 413, 1441
 AGS-1C4D4, 6591
 akt, 6027
 AKT inhibitor, 384, 1202
 Albumin-bound paclitaxel, 5060, 8511
 Alcohol, 3513
 Alcohol consumption, 3517
 Alemtuzumab, 9226
 ALEX1, 6145
 Algorithms, 8564
 ALK, 186, 9066
 Allogeneic stem cell transplantation, 9229
 Alopecia, 4227, 4242, 4245
 α -Fetoprotein, 1254
 Ambulatory care, 368
 Amelioration, 5
 American Joint Committee on Cancer staging system, 6529, 6622
 Ampullary carcinoma, 6547
 Amrubicin, 9105
 AN-152, 7043
 Anaemia, 3000, 3071, 4022, 4026, 9078, 9126
 Anal cancer, 6051, 6058, 6084, 6520, 6539
 Anal squamous cell carcinoma (ASCC), 6520
 Analgesedation, 4128
 Anaplastic astrocytoma, 4117
 Anaplastic lymphoma kinase, 301, 1007
 Anastomotic leakage, 2516
 Androgen, 6565, 7047
 Androgen deprivation syndrome, 7112
 Androgen deprivation therapy, 4034, 7042, 7101, 7104
 Angiogenesis, 73, 273, 378, 417, 1004, 1062, 1063, 1404, 1422, 8504
 Angiogenesis genes polymorphism, 1449
 Angiogenesis inhibitors, 7133, 7136, 7162, 9400
 Angiogenic cytokins, 4027
 Angiogenic factors, 7060
 Angiosarcoma, 9408
 Animal models, 272
 Annexin-A1, 1047
 Anorexia-cachexia, 4236

- Anthracyclines, 4127, 5058, 5078
 Anti-angiogenic molecules, 1080
 Anti-angiogenic therapy, 71, 75, 805, 1400, 6090, 6114, 7169
 Anti-angiogenics, 72, 1080, 7115, 8746
 Anti-apoptosis, 1054
 Anti-cancer drugs, 1074, 1307
 Anti-cancer drugs, delivery, 25
 Anti-CTLA-4, 89
 Anti-EGFR agents, 9126
 Anti-EGFR monoclonal antibody, 4125, 6107
 Anti-EGFR therapy, 6088
 Anti-emetics, 3072
 Anti-mullerian hormone, 4135
 Anti-neoplastic drug, 3629
 Anti-oestrogen, 3505
 Anti-oxidative and oxidative markers, 2023
 Anti-tumor activity, 1201, 8007
 Anti-tumor response, 6515
 Anti-VEGF antibody drug, 6107
 Anti-VEGF therapy, 7113, 8702
 Antibiotics, 3082, 9232
 Antibodies, 91, 92, 1078, 1242, 9305
 Antibody-dependent cell-mediated cytotoxicity, 1092
 Antibody proteomics technology, 9068
 Anticipatory nausea, 3020
 Antimycin A, 1027
 Antitumor activity, 8710
 Anxiety, 4123, 4190, 4199
 Anxiety-depression, 4215
 APC activation, 7011
 Apolipoprotein E, 6508
 Apoptosis, 354, 1018, 1023, 1026, 1036, 1089, 1118, 1122, 1212, 1228, 1413, 6129, 6507, 7116, 9207, 9310, 9311, 9410
 Apoptosis induction, 1028, 1211
 Aprepitant, 3065, 3068, 3079, 8536
 Arc therapy, 2064
 Arecanut, 8608
 ARF4, 8712
 Arm morbidity, 4172
 Aromatase inhibitors, 4019, 4231, 5069, 5104, 5162, 5163
 Aronia melanocarpa, 9206
 Array CGH, 801
 Artefacts, 2012
 Artemisinin, 1227
 Arteriovenous malformation, 8731
 Arthralgia, 4231
 Artificial hydration, 3024
 Artificial neural networks, 9040
 AS04-adjuvanted vaccine, 8047
 ASCC in HIV, 6520
 Ascites, 1016
 Ascites symptoms, 3080
 Asian ethnicity, impact in gastric cancer, 6617
 Aspiration pneumonia, 8553
 Aspirin/NSAID, 6157
 Assessment of care, 5035
 Assessment of patient needs, 4259
 Assessment of treatment response, 195
 Astrocytoma, 8712
 Asymptomatic bone metastases, 5034
 Asymptomatic brain metastases, 9313
 Attitudes, 410, 3024, 5188
 Audit, 3622, 6001
 Aurora kinase, 1110
 Autologous hematopoietic stem cell transplant, 3623
 Autologous heterotopic transplant of peripheral blood, 9079
 Automatic segmentation, 2100
 Autophagy, 1002, 1034, 1115
 AV integrin inhibitor, 7013
 Avastin, 9112
 Axillary lymph node dissection, 5014, 5041, 5116, 5139, 5144
 Axillary lymph node management, 5135
 Axillary metastases, 5044
 Axillary recurrence, 5041
 Axitinib, 3006, 7103, 7140
 Azacytidine, 1318
 Azathioprine, 9239
 B cell, 1200, 9325
 BAFF, 9232
 Basal phenotype, 5180
 Base of tongue squamous cell carcinoma, 8521
 Basic fibroblast growth factor, 7113
 Bax, 6608
 BBP, 6150
 BCL10, 9232
 Bcl2, 1413, 8733, 9203, 9235
 BCL3, 9232
 bcr-abl transcripts, 9242
 Behavioural animal model, 1167
 Behavioural change, 3028
 Belinostat, 6597, 7105
 Benign liver nodules, 2156
 Benzo[c]phenanthridine alkaloids, 9310
 Benzodiazepines, 343
 Best Practice in lymphoedema management, 294
 β -Catenin, 6027
 β -Catenin pathway, 6028
 11 β -Hydroxysteroid dehydrogenase I, 8008
 β -Tubulin III, 5080
 Bevacizumab, 272, 803, 804, 1093, 1135, 1402, 1412, 1414, 1415, 1418, 1423, 3604, 5049, 5051, 5053, 5064, 5072, 5073, 6003, 6004, 6013, 6093, 6094, 6098, 6112, 6113, 6124, 6132, 6133, 6142, 6150, 8002, 8003, 8703, 8747, 8750, 8751, 8752, 8753, 9003, 9020, 9073, 9076, 9086, 9090, 9112, 9135
 BH3-mimetics, 9024
 BIBW 2992, 9007
 Bilateral breast cancer, 1051, 5038
 Bile acid malabsorption, 7032
 Bile duct adenocarcinoma, 6623
 Bile duct cancer, 1107
 Biliary tract cancer, 6559, 6575, 6580, 6595, 6596, 6626, 6639
 Bio-immune-chemotherapy, 6140
 Biochemical failure, 7020
 Biofeedback, 4123
 Biological agents, 5054, 6599
 Biological therapies, 190, 3068, 6006
 Biology predictors, 250
 Bioluminescence, 2110
 Biomarkers, 138, 194, 222, 266, 269, 395, 800, 802, 804, 1103, 1135, 1138, 1139, 1140, 1141, 1150, 1310, 1422, 1424, 1431, 1434, 1435, 1443, 1447, 5082, 5147, 5179, 6126, 6133, 6577, 6604, 7107, 7161, 8746, 8755, 9003
 Biopsy, 398
 Biosimilars, 4022
BIRC5 gene, 7116
 Bisphosphonates, 3062, 5112, 7104
 BKM120, 9236
 Bladder, 7129, 7138, 7159
 Bladder cancer, 2103, 7105, 7119, 7121, 7127, 7172
 Bladder cancer, risk factors, 3531
 Bladder irrigation, 6057
 Bladder preservation, 7121

- Blood group, 5081, 6135
- Blood plasma factors, 803
- Blood pressure, 7140
- Blood samples, gene expression analysis, 1409
- BMS099, 9001, 9089
- Body image, 4243
- Body mass index (BMI), 165, 5198
- Body oncology, 109
- Body perception, 4207
- Boldine, 8710
- Bombesin antagonist, 7037
- Bone-directed therapy, 1074
- Bone loss, 5201
- Bone markers, 3044, 7061
- Bone marrow, 4114
- Bone marrow biopsy, 3058, 9240
- Bone marrow-derived cells, 1066
- Bone marrow disease, 4122
- Bone marrow metastasis, 2104
- Bone metastases, 259, 2043, 3010, 3018, 3062, 3613, 5007, 5034, 6624, 7003, 7004, 9148, 9149
- Bone mineral apparent density, 4120
- Bone mineral density loss, 7104
- Bone pain, 192
- Bone scan, 7063
- Bone tissue regeneration, 1081
- Boost planning, 5123
- Bortezomib, 7106
- Bowel cancer, 79
- Bowel symptoms, 79
- Bowell obstruction, 3003
- BPR1K653, 1110
- Brachytherapy, 366, 6002, 6056, 7022, 7025, 7034, 7126, 8018
- BRAF* gene, 129, 1002, 1156, 1403, 6041, 6131, 6141
- BRAF* mutation, 6138
- BRAF* V600E, 300, 1403
- Brain cancer, 5059, 8714, 8758
- Brain mapping, 237
- Brain metastases, 2064, 5036, 5061, 5084, 5089, 5098, 6141, 7059, 8706, 8726, 8727, 8728, 8735, 8737, 8740, 8760, 9017, 9069, 9070, 9306, 9328, 9412
- Brain tumours, 308, 1406, 2100, 4101, 4102, 4118, 4125, 4137, 8713, 8721, 8742, 8754, 8755, 8759
- BRCA1, 247, 268, 5080, 9004, 9142
- BRCA2, 247, 267
- BRCA1/2, 1130, 5172, 5184, 6632, 8046
- BRCA1/2 germline mutation, 3528
- BRCA1/2 mutation, 1462
- BRCA carriers, 3532
- BRCA genes, 5101
- BRCA mutation, 1453
- Breakthrough cancer pain, 3057, 4175, 4176
- Breakthrough pain, 3011, 3012, 3013
- Breast, 367, 1222, 2150, 3619, 4210, 5038, 5039, 5043, 5054, 5057, 5062, 5102, 5106, 5116, 5123, 5124, 5126, 5129, 5191
- Breast cancer, 35, 115, 120, 122, 223, 225, 248, 263, 264, 267, 313, 314, 315, 316, 362, 364, 365, 366, 1000, 1009, 1017, 1046, 1053, 1065, 1076, 1090, 1093, 1104, 1120, 1212, 1221, 1227, 1228, 1405, 1420, 1426, 1432, 1437, 1438, 1445, 1451, 1462, 2102, 2109, 2161, 2504, 3043, 3053, 3059, 3072, 3501, 3505, 3506, 3513, 3516, 3522, 3534, 3538, 3539, 3625, 3632, 4003, 4014, 4160, 4166, 4171, 4172, 4179, 4185, 4190, 4204, 4213, 4231, 4246, 4255, 4258, 5004, 5007, 5011, 5012, 5017, 5019, 5020, 5021, 5022, 5024, 5034, 5035, 5036, 5037, 5040, 5042, 5044, 5047, 5048, 5049, 5055, 5061, 5078, 5080, 5081, 5084, 5085, 5087, 5090, 5092, 5097, 5098, 5100, 5101, 5103, 5105, 5107, 5108, 5109, 5110, 5112, 5113, 5115, 5118, 5119, 5120, 5127, 5128, 5140, 5145, 5147, 5148, 5149, 5150, 5152, 5155, 5156, 5157, 5158, 5160, 5164, 5167, 5172, 5177, 5180, 5181, 5182, 5183, 5187, 5189, 5190, 5193, 5195, 5197, 5200, 5201, 5202
- Breast cancer, influence of energy balance, 167
- Breast cancer, predisposition, 1051
- Breast cancer, prognosis, 5095
- Breast cancer, progression, 1070
- Breast cancer, radiotherapy, 5121
- Breast cancer, risk, 5188
- Breast cancer, screening, 5131
- Breast cancer, subtypes, 5064, 5068, 5091, 5196
- Breast cancer, young women, 5031
- Breast cancer cells, 1118
- Breast cancer survivors, 4177
- Breast carcinoma, 1448, 5030, 5114, 5117, 5144
- Breast care nurse, 4185, 4186
- Breast-conserving therapy, 313, 2055, 5133, 5143, 5192
- Breast irradiation, 2022
- Breast neoplasm, 5139, 5169
- Breast reconstruction, 4229, 4254
- Breast screening, 5134
- Breastfeeding, 4255
- Breathlessness, 343
- Brentuximab vedotin, 9201
- Burkitt's lymphoma, 1037, 1122
- Burnout, 4241
- Burnout syndrome, 2070
- c-FLIP, 1027
- c-kit, 8600
- C-medium from T-lymphocytes, 1159
- c-Met inhibitor, 1245, 1246
- c-Myc, 14, 1442
- C-reactive protein, 9322
- CA19-9, 1463
- Cabazitaxel, 7044
- Cachexia, 3063, 9067
- Cadherin, 1067
- Caffeic acid phenethyl ester, 9207
- Calpain, 5180
- Calreticulin, 1076
- Calypso® system, 7033
- Cancer, 96, 166, 214, 240, 334, 341, 343, 353, 376, 1011, 1058, 1235, 1436, 1454, 2021, 2026, 3013, 3015, 3077, 3521, 3530, 3610, 4159, 4161, 4200, 4202, 4210, 4272, 5038, 5106, 5191, 6638
- Cancer, imaging, 195
- Cancer, in older patients, 216
- Cancer, in the elderly, 312
- Cancer, incidence, 336, 3508
- Cancer, incidence/mortality, 333
- Cancer, metastasis, 1069
- Cancer, prevention, 3537
- Cancer, prognosis, 1435
- Cancer, progression, 8713
- Cancer, therapy, 150, 395
- Cancer, vaccine therapy, 1108
- Cancer, waiting times, 3523
- Cancer biology, 87
- Cancer cachexia, 9137
- Cancer care, 309, 3630, 4197
- Cancer care units, 245
- Cancer cell lines, 1145
- Cancer drug cost, 43

- Cancer immunotherapy, 1001
 Cancer nursing, 8025
 Cancer of unknown primary, 1132, 1450, 9437
 Cancer pain, 1225, 3011
 Cancer patients, 4205, 4215, 4219
 Cancer physicians, 3046
 Cancer Plan, 4193
 Cancer registries, 93, 196, 3518
 Cancer-related anorexia cachexia, 3073
 Cancer-related fatigue, 3076, 5190
 Cancer screening, 3639
 Cancer-specific survival, 1411, 6051
 Cancer spending, 43
 Cancer stem cells, 81, 161, 239, 1016, 1017, 1108, 1406, 7107, 8754
 Cancer stem/tumor-initiating cells, 1019
 Cancer surgery, 4168
 Cancer survivors, 79, 4250, 6017, 8022
 Cancer symptoms, 10
 Cancer testis antigens, 9238
 Cancer-treatment induced bone loss, 117
 Capecitabine, 5053, 5057, 6003, 6004, 6047, 6593, 8034
 Capecitabine and oxaliplatin, 6103, 6598
 Capecitabine dose, 5096
 Capecitabine maintenance, 6600
 Capsaicin, 3017
 Carbohydrate intake, 3510
 Carbon ion beam, 2029
 Carbon-ion radiotherapy, 2040, 8517
 Carbon nanotube, 1214
 Carbonic anhydrase IX, 8720
 Carbonic anhydrases, 121
 Carboplatin, 123, 4001, 5199, 8048, 8749
 Carboxy-hemoglobin, 8503
 Carcino-embryonic antigen, 6054, 6068
 Carcinogenesis, 1050
 Carcinoid, 6581, 6628
 Carcinoid tumor, 9097
 Carcinoma, 4121, 6559, 8010
 Carcinoma, penis, 7126
 Carcinoma, rectum, 6055
 Carcinoma-associated fibroblasts, 1064, 1164
 Carcinoma of unknown primary site, 1150, 1259
 Carcinomatous meningitis, 9151
 Cardiac function, 9221
 Cardiac repolarization, 1244
 Cardiopulmonary exercise testing, 4015, 4168, 6545, 6546
 Cardiotoxicity, 1114
 Cardiovascular disease, 4007
 Care burden, 4216
 Care coordination, 3608, 3609
 Care delivery, 9, 368, 369, 370, 2153, 4161, 4191, 4216, 4226, 4235
 Career planning, 170
 Caring, 4154
 Caring behaviours, 4197
 Carnitine, 3073
 Caspase-3, 1089
 Castration-resistant prostate cancer, 3602, 7000, 7001, 7008, 7014, 7015, 7016, 7021, 7046, 7047, 7048, 7053, 7055, 7056, 7057, 7058, 7059
 Catumaxomab, 1428, 3080, 8007, 8032
 Causality, 5087
 CB1 CB2 receptors, 1237
 CCL2, 120
 CCL5, 8011
 CD133, 1016, 6023, 8707
 CD200, 9215
 CD133 expression, 1019
 CD26 expression, 1077
 CD40 pathway, 1119
 CD11b + monocytes, 36
 CDDP + S-1 combination therapy, 1259
 Celecoxib, 3073
 Cell biology, 9324
 Cell cycle, 9405
 Cell cycle arrest, 1022
 Cell cytoskeleton, 1008
 Cell death, 1001, 1028
 Cell division, 1454
 Cell migration, 1055, 1073, 9307
 Cell migration/adhesion, 6024
 Cell proliferation, 1052, 8520
 Cell response to protons, 2006
 Cell saver, 6008
 Cell uptake of nanoparticles, 1224
 Cell vehicle, 2110
 Cell-cell communication, 1166
 Cell-cell interactions, 405
 Census, 4181
 Central contact unit, 4188
 Centralization, 6503
 Centralized units, 1313
 Cerebral gliomas, 8717
 Cervical cancer, 53, 296, 297, 298, 3534, 8000, 8001, 8016, 8018, 8020, 8024, 8027, 8041, 8044, 8052, 8053
 Cervical cancer, prevention, 52
 Cervical cancer, risk, 8037
 Cervical cancer, screening, 54, 8010
 Cervical carcinoma, 8009, 8014
 Cervical intraepithelial neoplasia, 8009, 8045
 Cervical lesions, 1062
 Cervical screening policy, 52
 Cetuximab, 1005, 1429, 4267, 6014, 6015, 6044, 6122, 6140, 6526, 6559, 8513, 8529, 8558, 8570, 8585, 8594, 9000, 9001, 9019, 9034, 9089, 9096
 Characteristics of soft-tissue sarcomas, 9432
 Characterization of circulating tumour cells, 304
 Checkpoint, 92
 Checkpoint kinase 2, 1113
CHEK2 gene, 1128
 Chemo-immune-therapy, 6106
 Chemoembolisation, 6048, 6064, 6517
 Chemoperfusate distribution, 2505
 Chemoport, 8013
 Chemoprevention, 9326
 Chemoradiotherapy (CRT), 41, 4011, 4265, 5122, 6033, 6038, 6044, 6050, 6053, 6054, 6060, 6522, 6526, 6529, 6531, 6544, 7121, 8000, 8001, 8014, 8536, 8543, 8549, 8574, 8606, 9044, 9049, 9060, 9222
 Chemoresistance to paclitaxel, 1410
 Chemosensitivity, 1168, 5068
 Chemotherapy, 34, 67, 190, 257, 292, 296, 417, 1014, 1088, 1145, 1202, 1312, 3002, 3017, 3025, 3048, 3053, 3055, 3066, 3078, 3082, 3509, 3514, 3635, 4005, 4026, 4133, 4179, 4227, 4242, 5025, 5079, 5105, 6009, 6050, 6094, 6548, 6562, 6583, 6589, 6601, 6605, 7021, 7045, 7048, 7138, 7146, 8012, 8034, 8531, 9006, 9014, 9029, 9056, 9085, 9102, 9107, 9109, 9124, 9125, 9146, 9225, 9228, 9300, 9424, 9426
 Chemotherapy, complications, 3001
 Chemotherapy, decision, 4008
 Chemotherapy, prescription, 1316
 Chemotherapy, response, 5078

- Chemotherapy, sensitivity, 5177
 Chemotherapy day units, 4218
 Chemotherapy-induced alopecia, 3009, 3050, 3054
 Chemotherapy-induced anaemia, 3049, 3620
 Chemotherapy-induced nausea and vomiting, 3007, 3065, 3072, 3079
 Chemotherapy resistance, 5082
 Chernobyl accident, 3508
 Chest wall, 9415
 Childhood and adolescent, 23
 Childhood cancer, 20, 21, 50, 173, 354, 3042, 3512
 Childhood leukaemia, 173
 Children, 4, 102, 103, 105, 200, 324, 4100, 4112, 4116, 4117, 4120, 4123, 4130
 Chimerism, 9226
 Choi criteria, 1400, 1401
 Cholangiocarcinoma, 290, 291, 1030, 1463, 3500, 6128, 6522, 6533
 Chondrosarcoma, 9435
 Chromogranin A, 6564
 Chromosomal instability, 1050
 Chronic fatigue, 5087
 Chronic lymphocytic leukaemia, 131, 9204, 9209, 9215, 9234, 9236
 Chronic myeloid leukaemia, 9233
 Chronological data, 3500
 Circulating tumour cells, 203, 303, 304, 1020, 1426, 1440, 5021, 5022, 5090, 6003, 6004, 7014
 Circumferential resection margin, 6085
 Cisplatin, 34, 146, 1204, 3078, 4130, 6567, 9024, 9080, 9099, 9106
 Cisplatin adjuvant chemotherapy, 9009
 Claudin, 7117, 7118
 Claudin-1, 1084
 Claudin-4, 1438
 Claudin expression, 6611
 Clear cell carcinoma of the ovary, 8005
 Clinical demands, 4030
 Clinical guidelines, 167, 3007
 Clinical judgment, 1306
 Clinical nurse specialist (CNS), role, 4229
 Clinical outcomes, 6102, 7027, 9434
 Clinical pharmacy, 3078
 Clinical practice, 3069, 6103
 Clinical proteomics, 140
 Clinical research nurse, 4192
 Clinical research software, 2163
 Clinical routine practice, 3640
 Clinical trials, 114, 262, 276, 1255, 1304, 1311, 4107, 4192, 4204, 4223, 6511, 8716
 Clinical trials, design, 157, 273, 1206
 Clinical trials, simulation, 5096
 Clinically meaningful difference, 3035
 Clinician scientist, 170
 Clinicopathological features, 5099, 5111, 6032
 Clonogenic assay, 2005
 CMF chemotherapy, 5055
 CNS metastases, 5032
 Coagulation, 1126
 Cognitive functioning, 1167, 4179, 5105, 7132
 Cognitive impairment, 115
 Cohort study, 3510, 4177
 Collaboration, 356
 Collagen type I telopeptide (NTx), 9149
 Colon cancer, 77, 317, 318, 1031, 4009, 4020, 6028, 6030, 6075, 6076, 6082, 6102, 6117, 6129, 6161
 Colon cancer, influence of energy balance, 167
 Colon cancer, progression, 6024
 Colon carcinoma, 6108
 Colonic tumour location, 6032
 Colorectal cancer, 29, 136, 138, 141, 178, 319, 1005, 1010, 1101, 1146, 1402, 1418, 1427, 1429, 1439, 2020, 2507, 2510, 2516, 3063, 3612, 3614, 3617, 3640, 4005, 4017, 4178, 4201, 6007, 6009, 6011, 6014, 6019, 6021, 6022, 6023, 6025, 6026, 6029, 6032, 6034, 6036, 6039, 6040, 6041, 6063, 6065, 6066, 6067, 6080, 6087, 6090, 6092, 6093, 6097, 6100, 6106, 6107, 6110, 6119, 6122, 6123, 6124, 6133, 6135, 6136, 6138, 6139, 6140, 6145, 6146, 6151, 6153, 6154, 6157, 6159, 6160, 6165, 9434
 Colorectal carcinogenesis, 6158
 Colorectal carcinoma (CRC), 6077
 Colorectal carcinoma (CRC), cell lines, 1019
 Colorectal liver metastases, 4015, 6010, 6068
 Colorectal neoplasms, 6086
 Combination therapy, 87, 147, 269, 1010, 1156, 1253, 6051, 6110, 7037, 8541, 8542, 9118
 Combined anticancer therapy, 5104
 Combined modality therapy, 251, 393, 8539, 9036, 9219
 Combined targeted therapy, 5173
 Common cancers, 94
 Common Terminology Criteria Adverse Events (CTCAE), 4155
 Common toxicity criteria, 4266
 Communication, 3636
 Communication instrument, 4222
 Community nursing, 4156
 Comorbidity, 388, 4007, 4016, 8509
 Companion diagnostic, 332
 Comparative assessment, 6069
 Comparative effectiveness, 6152
 Comparison, 1433
 Comparison, paclitaxel with cisplatin, 8579
 Competence to care emotionally, 410
 Competing mortality, 5015
 Complement activity, 6511
 Complementary and alternative medicine, 4165, 5119
 Complementary interventions, 4174
 Complete response, 8753
 Completion surgery, 8000
 Completion-time windows, 3035
 Complex interventions, 4247
 Complications, 217, 4162, 4271, 5002, 6074
 Comprehensive geriatric assessment, 4006, 4028, 4031
 Concentration of surgery, 3601
 Concept development, 4221
 Concomitant cetuximab cisplatin radiotherapy, 8545
 Concomitant chemotherapy and radiation therapy, 5199
 Concurrent chemoradiotherapy, 256, 8043, 9028, 9037
 Conditional survival, 6161
 Conditional survival nomogram, 6633
 Conditioning, 9226
 Cone-beam CT, 110, 2013, 2016, 7023
 Confocal microscopy, 1458
 Conformal 3D radiotherapy, 8717
 Conformal radiotherapy, 7029
 Conformity index, 2050
 Consequences of cancer, 3008
 Continuity of care, 369, 4235
 Continuous endpoints, 421
 Contralateral prophylactic mastectomy, 5184
 Conversion chemotherapy, 6073
 Coping strategies, 4167
 Coplanar and non-coplanar techniques, 2062
 Copy number, 5185
 Cord compression, 4170

- Cosmesis, 8518
 Cost, 3600, 6148, 6638, 9113
 Cost-effectiveness, 2155, 3050, 3606, 3612, 3617, 5194, 8050
 Cost of illness, 3605
 Cost saving, 1305
 Cough, 116
 Counseling, 3540
 Couple relationship, patient–caregiver, 4202
 COX-2 inhibitor and EGFR inhibitor, 8589
 cPSA, 1433
 CPT11 and panitumumab, 6144
 Craniopharyngioma, 8724
 Craniospinal irradiation, 4129
 Creatinine clearance, 1232
 Critical appraisal, 9100
 Critical reading, 358
 Crizotinib, 186, 332, 3030, 9084
 Cross-contamination, 1317
 Crossover, 158
 CRP, 1457
 Cryopreservation, 9230
 CT, 7108
 CT colonography, 6154
 CT-MR fusion, 2014
 CT-MR image registration, 2014
 CT number, 8577
 CT scan, 2100, 2101
 CTLA-4, 1446
 Cultural issues, 4256
 Cultures, 3511
 Curative non-surgical therapy, 8514
 Curative radiotherapy, 9046
 Curcumin analogue, 5085
 Curcuminoids, 7045
 Cutaneous manifestation, 1249
 Cutaneous metastases, 5049
 CXCR4, 6512
 Cyclophosphamide, 5199
 Cyfra 21-1, 5023
 Cylindrical abdominoperineal resection, 6085
 CYP3A7, 6158
 CYP3A4*1B, 1152
 CYP2D6, 5171, 5185
 Cyr61, 1041, 1106, 1146
 Cystectomy, 7128
 Cysteine rich 61, 1041, 1106, 1146
 Cytochrome P450 2D6, 5171, 5185
 Cytogenetics, 9234
 Cytokeratin, 9025
 Cytokine, 3039, 9333
 Cytology, 1094, 3529, 5137
 Cytoreductive surgery, 30, 31, 2508, 6074

 4D-CT, 2007, 2039, 2056, 2065, 6535, 6538, 9043
 D-Dimer, 1102, 9406
 DAB2IP, 1148
 Dacarbazine, 4021, 9319, 9321
 DAPK, 8505
 Darbepoetin alfa, 3049, 3620
 Data management, 2162
 Data sharing infrastructure, 2161
 DCE-MRI, 1205
 DCE-US, 63, 805, 7169
 DEADbox, 1151
 Decision-making, 4203, 4204
 Decision support, 196
 Decoy receptor 3, 9410

 Deformable image registration, 2039
 Deformable registration, 2008, 9021, 9051
 Dehydration, 1461
 Dehydroepiandrosterone, 5074
 Delay in diagnosis, 49, 4206
 Delay of onset of adjuvant chemo- or radiation therapy, 5141
 Delayed nausea and vomiting, 3056
 Dendritic cell vaccination, 9329
 Dendritic cells, 8039
 Denosumab, 3051, 3061, 3602, 3603, 7004
 Depression, 4199
 Dermal lymphatic invasion, 5077
 Dermatitis in breast cancer, 5124
 Dermatitis in head and neck cancer, 8562
 Desensitization, 1302
 Designs, 86
 Desmoid, 413
 Desmoid tumours, 414, 1441, 9415
 Developing country, 3506
 DeVIC, 9222
 Dexamethasone, 9108
 DHA, 1032
 Diabetes mellitus, 333, 334, 336, 5117
 Diabetes mellitus, treatment, 333
 Diagnosis, 1459, 4101, 4194, 5202, 7170, 8704
 Diagnosis and prognosis, 8040
 Diagnostic pathway, 8759
 Dietary intervention, 4163
 Dietary risk factors, 8599
 Differential expression, 8712
 Diffuse large B-cell lymphoma, 133, 3515
 Diffuse large B-cell NHL, 2105
 Diffuse pontine glioma, 4118, 4125
 Diffuse reflectance spectroscopy, 2150, 2157
 Diffusion-weighted MR, 2012
 Digital questionnaires, 4220
 Dimethyl sulfoxide, 2023
 Direct sequencing, 1142
 Disclosure of sexual orientation, 152
 Discordant rate, 6136
 Disease-free survival, 6160, 9414
 Disease outcome, 5077
 Disease progression, 9209
 Displacement correlation, 2028
 Disseminated tumour cells, 303
 Distant progression, 7101
 Distress, 3081
 DMET platform, 1040
 DNA damage, 5092, 9026
 DNA damage response, 1125
 DNA hypermethylation, 9074
 DNA methylation, 1000, 8505
 DNA microarray, 9237
 DNA-PK, 9204
 DNA repair, 1125, 9009, 9308
 DNA vaccination, 1007, 9320
 DNA vaccine, 59, 1254
 Docetaxel, 1224, 1432, 5058, 5060, 5062, 5075, 5199, 6593, 7044, 7049, 7050, 7059, 8585, 9099
 Docetaxel and cisplatin, 9037
 Docetaxel and cisplatin-fluorouracil, 7110
 Docetaxel rechallenge, 7052
 Docetaxel-resistant prostate cancer, 7053
 Dose accumulation, 9051
 Dose dense, 7138
 Dose distribution, 9045
 Dose escalation, 1230, 1245, 1246, 7031

- Dose-escalation, 8555
- Dose-painting, 106, 2152
- Dose per pulse, 2005
- Dose prescription, 2063
- Dose reduction rate, 9108
- Dose volumetric parameter, 9050
- Dose-volume histogram, 2048, 7031
- Dosimetry, 2008, 2049, 2062, 7022
- Double arc, 2047
- Doxorubicin, 9103
- DPD, 5080
- DPPIV activity, 1077
- Drawing as expression of relationship, 4202
- DREV1, 1072
- Driver mutation, 143
- Drug absorption, 241
- Drug delivery, 27, 28, 1218
- Drug development, 200, 332, 1304
- Drug interaction, 7058
- Drug resistance, 246, 381, 1110, 1117, 6021, 7017
- Drug screening, 4102, 4137, 5003, 8754
- Drug stability, 1307
- Dual PI3K/mTOR inhibitor, 2020
- Ductal carcinoma in-situ (DCIS), 5131, 5134
- Dukes's classification, 6019
- Duodenal GIST, 9413
- Duodenectomy, 9413
- Durable complete remission, 5000
- Dying, 409
- Dynamic contrast enhanced ultrasonography, 63, 805, 7169
- Dysphagia, 8552
- Dyspnoea, 341, 344

- E7080, 1097
- E-cadherin, 1013, 1438, 9061
- E-Health, 11
- Early detection, 140
- Early diagnosis, 8053
- Early evaluation, 805
- Early phase therapy trials, 266
- Early prediction, 5013
- Early response evaluation, 1402
- Early stage breast cancer, 5008, 5015, 5125, 5135, 5194
- Early stage breast carcinoma, 2503
- Early stage glottic cancer, 8559
- Early stage non-small cell lung cancer, 403
- EC FP7 project, 171, 172
- ECOG, 4033
- Economic analysis, 3604
- Economic burden, 3605
- Economic impact, 5161
- ED-SCLC, 9105
- Education, 208, 3636, 4175, 4238, 8607
- Education of nurses, 4228
- Educational training, 4196
- E2F1, 1023
- E2F2 transcription factor, 6024
- Efatutazone, 1238, 9059
- Efficacy, 1105, 1260, 3054, 6123, 8749
- EGFR-TKI treatment, 1117, 9088, 9093, 9115
- Eicosapentaenoic acid, 9145
- Elastic registration, 2034
- Elderly patients, 65, 217, 218, 225, 388, 4000, 4001, 4002, 4003, 4005, 4008, 4009, 4010, 4011, 4012, 4016, 4018, 4019, 4020, 4023, 4024, 4027, 4028, 4032, 4033, 5015, 5072, 6071, 6113, 8020, 8514, 8547, 8561, 8721, 9073, 9088, 9123
- Elderly patients, NSCLC, 9095
- Electrochemotherapy, 9312
- Electromyostimulation, 6163
- Electron beam energy, 2025
- Electron radiotherapy, 9314
- Electronic Case Report Form, 2162
- Electronic health records, 184, 196
- Embryos, 150
- Emergency surgery, 6070
- Emetic guidelines, 3048
- EML4-ALK, 327, 9062
- Emotion, 3027
- Employment, 4249
- Empowerment, 4213
- Empty bladder, 7040
- End-of-life, 3014, 3024, 6589
- End-of-life care, 3025, 4156
- End of treatment, 4233
- Endocrine-responsive, 5016
- Endocrine symptom assessment, 360
- Endocrine therapy, 361, 5017, 5158
- Endocrine therapy and chemotherapy, 5175
- Endometrial cancer, 222, 1106, 1459, 8033
- Endometrial carcinoma, 1057, 8021, 8023
- Endoscopic access, 8581
- Endoscopic mucosal resection, 6629
- Endoscopic recanalization, 6087
- Endoscopic surgery, 5008
- Endothelial progenitor cells, 1068
- Endothelin, 6125
- Endotoxin, 2045
- Endpoints, 86, 163, 164, 3607
- Energy ablation, 213
- Energy balance, influence on breast/colon carcinogenesis, 167
- Enhanced cell-uptake, 1223
- Enhanced recovery, 4015
- Enoxaparin, 1123
- Enrollment, 1256
- Enteral nutrition, 4236
- Environmental tobacco smoke, 3519
- Environmental contamination, 3629
- Enzastaurin, 9069
- EORTC QLQ-C30 Version 3.0, 9091
- EpCAM, 1094, 1428
- EphA10, 5028, 5029
- Ephrin receptor A10, 5028, 5029
- Epidemiological database, 3640
- Epidemiology, 21, 93, 3502, 3503, 3506, 3524, 5031, 5191, 9015, 9057, 9432
- Epidermal carcinoma, 8556
- Epidermal growth factor (EGF), 8527, 9139
- Epidermal growth factor receptor (EGFR), 347, 1043, 1055, 1158, 1417, 4024, 4267, 7155, 8044, 8756, 9002, 9016, 9087, 9092, 9138
- Epidermal growth factor receptor (EGFR), FISH, 9007
- Epidermal growth factor receptor (EGFR), inhibition, 147
- Epidermal growth factor receptor (EGFR), mutations, 327, 1148, 1455, 3529, 9004, 9015, 9017, 9101, 9115, 9122, 9123, 9132, 9134, 9136, 9141, 9144, 9150
- Epidermal growth factor receptor (EGFR) antibody, 6109
- Epidermal growth factor receptor (EGFR) tyrosine kinase, 9151
- Epigallocatechin gallate, 9217
- Epigenetic markers, 802
- Epigenetic remodelling, 1410
- Epigenetic therapy, 6597
- Epigenetics, 96, 134, 227, 1036
- Epigenetics, of NSCLC, 9074

- Epirubicin, 5199
 Epirubicin cardiotoxicity, 1261
 Epithelial ovarian cancer, 8049
 Epithelial–mesenchymal transition (EMT), 1067, 1117, 1132, 1134
 Epithelial–mesenchymal transition (EMT), marker, 8524
 Epithelioid hemangioendothelioma, 9433
 Epitope masking, 5027
 Epoetin, 4022
 Epoetin alfa, 3049
 EpSSG, 101
 EQ-5D questionnaire, 3043
 ErbB-3/Akt pathway, 1226
 ERCC1, 8043
 Eribulin mesylate, 1243, 1244, 5006
 ERK, 1021
 Erlotinib, 123, 6567, 6577, 8711, 9016, 9087, 9100, 9119, 9121, 9127, 9129
 Erythropoiesis-stimulating agent, 3066
 Esophageal adenocarcinoma, 6565
 Esophageal cancer, 153, 155, 235, 2049, 3517, 3644, 6518, 6526, 6529, 6531, 6535, 6552, 6607, 8510
 Esophageal cancer, radiotherapy, 2027, 2028
 Esophageal carcinoma, 6527, 6601
 Esophageal neoplasms, radiotherapy, 6541
 Esophageal squamous cell carcinoma, 6558, 6602
 Esophagectomy, 6552
 Esophagus, 6550
 Esthesioneuroblastoma, 8531
 Estrogen receptor, 1053, 6025
 Estrogen receptor α , 1151
 Estrogen receptor α 36, 1054
 Estrogen receptor antagonist, 5070
 Estrogen-receptor negative breast cancer, 1237
 Ethics, 1311
 European directives, 103
 European Medicines Agency, 156, 357
 Evaluation of quality of care, 3637
 Everolimus (RAD001), 5005, 6560, 6561, 6566, 6571, 6572, 6573, 6581, 6585, 6626, 6628, 8502
 Evidence-based guidelines, 4269
 Evidence-based medicine, 3644
 Evidence for therapies in lymphoedema management, 294
 Ewing family tumors, 4122
 Ewing's sarcoma, 276, 4131, 9414
 ExacTrac 6D, 2051
 Excess mortality, 9022
 Exenterations, 6046
 Exercise, 3055, 4171
 Exosomes, 1166, 7017
 Expanded access, 7134
 Experience, 80, 4195
 Exploratory biomarkers, 9089
 Exposome, 95
 Expression, 1046
 Expression profile, 9030
 Extended survival, 9404
 External-beam partial breast irradiation, 2055
 Extracapsular spread, 5120
 Extracellular matrix, 119
 Extracranial lesions, 4124
 Extrahepatic bile duct cancer, 6544
 Extranodal NK/T-cell lymphoma, 9222
 Extrasosseous Ewing's sarcoma, 9414
 Extrapleural pneumonectomy, 9032
 Extrapulmonary small cell carcinoma, 9332
 Extravasation, 4189
 Extraventricular neurocytoma, 8732
 Extremity, 9418
 EZH2, 8712
 Failed chemoradiation therapy, 6084
 FAK, 1165
 Familial and sporadic breast cancer, 3535
 Familial cancer, 3626
 Fatigue, 3019, 3036, 3055
 FBT, 3012
 FCGR polymorphisms, 1429
 FDG-PET, 56, 6524, 6527, 6627, 8540
 FDG-PET/CT, 1408, 2104, 5013, 9011
 Febrile neutropenia, 3015, 3045, 3047, 3069, 3082, 3509, 3533, 9082
 FEC, 5063
 Fecal elastase-1, 6636
 Fentanyl, 3013, 3016, 3057
 Fermented wheat germ extract lyophilisate, 1228
 Fertility, 151, 298, 4135, 8027
 Fever, 3511
 [^{18}F]Fluorodeoxyglucose positron emission, 2000, 6519, 9010
 FFPE, 1409
 FGFR1, 188
 Fibroblast growth factors, 1095
 Fibromatosis, 415
 Fibrosis, 149, 5192
 Fiducial markers, 2012
 Filgrastim, 4025
 First failure site, 9049
 First-line therapy, 5071, 6585, 9000, 9015, 9019, 9144
 First-line therapy in advanced NSCLC, 9001, 9113, 9114
 Flat epithelial atypia, 5138
 Flattening filter-free beams, 2005, 2060
 Flavonoids, 1067
 Flims workshop, 231
 Flow chart, 4226
 Flow cytometry, 1119
 FLT3, 1251
 FLT-3 inhibitor, 1217
 FLT PET, 6541
 Fluid mechanics, 2505
 Fluorescence, 107, 1431, 9316, 9334
 Fluorescence angiography, 6550
 Fluorescence diagnostics, 8603
 Fluorescence in situ hybridization, 9234
 Fluoroazomycin-araboside, 19
 Fluoromisonidazole, 19
 Fluoropyrimidine, 6580
 Fluorothymidine, 1407
 5-Fluorouracil, 5199, 6120, 6575
 FNE, 7130
 Focal therapy, 2058
 Focus group, 5183
 Folate, 6119
 FOLFIRI, 1105
 Follicular lymphoma, 134, 3515
 Follow up, 1458, 4187, 4251, 6068, 6151
 Food effect, 241
 Fotemustine, 8703, 8743
 Four-dimensional CT, 2007, 2026, 2027, 2028, 2039, 2056, 2065, 6535, 6538, 9043
 Four-dimensional CT simulation, 2054, 2055, 6536, 6537
 Four-dimensional List Mode PET/CT, 2002
 FOXL2 mRNA, 8006
 Foxo3a, 1061, 1118
 Foxp3(+), 1416

- Fractures, 2057, 5155
 Frailty, 4006, 4028, 4031, 4032
 Frailty Index, 4033
 Frameless cranial radiosurgery, 2051
 Frameless stereotactic radiosurgery, 2061
 Free flaps, 168
 Free testosterone, 7053
 Front-line therapy, 8002
 FSH, 7112
 Fulvestrant, 1065, 5070
 Functional imaging, 62, 63, 7169, 8544
 Furin, 1240
 Furosemide, 341
 Fused Toes Homolog, 8045
- G-CSF, 3069, 4025, 7130
 G-CSF receptor, 5103
 G8 questionnaire, 4006
 Gabaxate mesilate, 1028
 Galectin-1, 255
 Gallbladder cancer, 292, 6549
 Gallbladder carcinoma, 6512
 Gamma-delta T cells, 1074
 γ -Glutamyltransferase, 8041
 Ganitumab (AMG 479), 6587, 6588
 Gantry tilt scan, 8577
 Gas chromatography, 1099
 Gastrectomy, 6523
 Gastric atrophy metaplasia dysplasia, 6509
 Gastric cancer, 328, 1024, 1063, 1415, 1419, 1460, 3032, 3605, 4004, 6502, 6504, 6505, 6507, 6508, 6513, 6514, 6521, 6523, 6528, 6551, 6555, 6562, 6570, 6578, 6579, 6583, 6585, 6586, 6590, 6608, 6610, 6611, 6612, 6614, 6617, 6624, 6625, 6627, 6633, 6635
 Gastroesophageal adenocarcinoma, 6609
 Gastroesophageal junction cancer, 6590
 Gastrointestinal cancer, 1038, 1235
 Gastrointestinal side effects of radiotherapy, 4163
 Gastrointestinal stromal tumor, 9405, 9411, 9436
 Gastrointestinal system cancers, 4008
 Gastrointestinal toxicity, 78
 Gastrointestinal tumours, 1020
 Gating, 6530
 Gb3, 9023
 GDC-0941, 1248, 9012
 Gefitinib, 9087, 9101, 9116, 9122, 9123, 9132, 9134
 Gemcitabine, 3525, 6111, 6567, 6580, 6596, 9008, 9028, 9095, 9127
 Gemcitabine/docetaxel combination, 9426
 Gemcitabine-refractory biliary tract cancer, 6595
 gemox regimen, 6575
 Gene expression, 4104, 5030, 5102, 9216
 Gene expression profiling, 1098, 1134, 5176
 Gene expression signature, 1093
 Gene polymorphisms, 3527, 6613
 Gene regulation, 12
 Gene therapy, 1109
 Genetic epidemiology, 6508
 Genetic hypersensitivity, 2010
 Genetic markers, 1136, 1412
 Genetic polymorphism, 9139
 Genetic variability, 1414
 Genetics, 133, 3540, 6019
 Genome sequencing, 143, 209
 Genome-wide association study, 94
 Genomic technology, 2160, 5114
 Genomics, 800
- Genotype, 5171
 Genotype-specific treatment, 131
 Geometry consisting of clips, 2055
 Geriatric assessment, 312
 Geriatric oncology, 216, 4021, 4029, 4191
 Germ cell, 7142, 7170
 Germ-cell tumours, 144, 7125, 7166
 Germ-line genetics, 94
 Germ-line mutations, 1131
 GFI, 4033
 GGH – 401C > T, 8037
 GIDEON study, 6500
 GIST, 1138, 1140, 1444, 7165, 9404, 9406, 9421, 9425, 9434
 GIST surgery, 2509
 Glasgow Prognostic Score, 6165
 Glial tumor, 8734
 Glioblastoma, 239, 272, 273, 802, 1116, 1241, 8701, 8703, 8711, 8721, 8733, 8743, 8744, 8746, 8756
 Glioblastoma multiforme, 4116, 8716, 8718, 8738, 8751
 Glioma, 162, 237, 271, 1421, 2110, 8704, 8708, 8710, 8713, 8745, 8747
 Glioma stem cells, 8707
 Global trials, 328
 Glomus caroticum, 8736
 Glomus jugulare, 8736
 Glottic cancer, 8534
 Glucocorticoid resistance, 9237
 Glucocorticoids, 1059, 8008
 Glutamine, 4274
 Glyco-PEGylation technology, 1215
 Glycolysis, 1015
 Glycoproteins, 1239, 1460
 Goitre, 8596
 Gonad dose, 2053
 Goshajinkigan, 6089
 Grading, 1437, 5126, 8527
 Graft versus host disease, 9229
 Gram-negative bacteria, 8598
 Granulosa cell tumours, 8006
 Green fluorescent protein, 1258
 Green tea extract, 1229
 GRN163L, 1008
 Groningen Frailty Index, 391
 Gross residual disease, 6544
 Gross tumour volume, 6536, 8557
 Grounded Theory, 323
 Growth factors, 1057, 1133
 Growth stabilization, 6630
 GSTP1, 5170
 GTV delineation, 6541
 Guidelines, 116, 118, 185, 214, 317, 1307, 3627, 3633, 4270
 Guidelines, adherence, 8602
 Guidelines, development, 3644
 Gut bacteria, 77
 Gutkha, 8608
 Gynaecological cancers, 4169, 4208, 6637, 8022
 Gynaecological malignancies, 8019
 Gynaecological oncology, 4226
- Haematologic malignancies, 9223
 Haematological cancers, 1200
 Haematological malignancy, 9230
 Haematology, 4248
 Haematopoietic stem cell transplantation, 4119
 Haematopoietic stem cells, 7060
 Haemoglobin, 4026, 8503
 Harmonic scalpel, 8580

- HART-CIS-CET, 8501
 HCC, 1254, 3634, 6500
 HCC, multifocal, 6563
 HCV, 3059
 HDAC inhibitors, 1234, 7054, 7105
 HE4, 1459, 8040
 Head and neck, 1081, 8516, 8529, 8532, 8537, 8561, 8590, 8600, 8606
 Head and neck cancer, 41, 82, 310, 391, 2041, 2046, 3031, 4164, 4236, 4243, 4262, 8504, 8505, 8508, 8509, 8510, 8513, 8515, 8535, 8539, 8543, 8544, 8546, 8549, 8563, 8576, 8585, 8588, 8589, 8597, 8602
 Head and neck carcinoma, 8522, 8551
 Head and neck squamous cell cancer, 8533, 8574
 Head and neck squamous cell carcinoma, 8594
 Head and neck surgery, 42, 389, 8507
 Health and illness, 4
 Health care decision makers, 175
 Health care expenditure, 3002
 Health care professionals, 4239
 Health care quality, 5035
 Health care staff performance, 4191
 Health Communication, 244
 Health economics, 69, 3614
 Health education, 3537
 Health information technology, 184
 Health-related quality of life, 3035, 3036, 3042, 9075, 9243
 Health resource utilisation, 3613
 Health services, 6152
 Health Technology Agency, 175
 Health technology assessment, 175, 3631
 Hearing preservation, 8700
 Heat shock protein 70 (Hsp70), 4126
 Heat shock protein 90 (HSP90), 1073
 Heat shock protein 90 (HSP90) inhibitors, 9407
 Heavily pretreated patients, 5006, 5055
 Hedgehog signalling pathway, 1009
 HeLa, 1033
 Helical tomotherapy, 3010, 4131, 8554, 8571
Helicobacter pylori, 6631, 9232
 Hemangioendothelioma, 9420
 Heparan sulfate mimetic, 1083
 Heparanase, 6022
 Hepatectomy, 6073, 6086, 6151, 6516, 6548
 Hepatic impairment, 5066
 Hepatic insufficiency, 6560
 Hepatic resections, 2502
 Hepatitis B virus, 3514
 Hepatobiliary intervention, 6545
 Hepatoblastoma, 4112
 Hepatocellular cancer, 6517
 Hepatocellular carcinoma, 372, 373, 1113, 2056, 2068, 2069, 2156, 6501, 6542, 6576, 6582, 6594, 6597, 6615
 Hepatocellular carcinoma and liver metastases, 2044
 Hepatoma cell lines, 1084
 HER2, 248, 396, 1049, 1417, 1464, 5002, 5050, 5065, 6015, 6602
 HER-2 expression, 1127
 HER2 inhibition, 5045
 HER2-negative metastatic breast cancer, 5053
 HER2 non-amplified breast cancer, 1092
 HER2 overexpression, 5174, 8051
 HER2 overexpression/amplification, 5173
 HER2-positive breast cancer, 5013, 5083
 HER2-positive breast cancers, 5003, 5067, 5187
 HER2-positive metastatic breast cancer, 5001
 HER2-HER3 signaling, 5004
 Herceptin, 4182
 Hereditary breast and ovarian cancer, 1130
 Hereditary breast cancer, 1128, 1131
 Hereditary cancer, 3540
 Hereditary colorectal cancer, 6035, 6045
 Hereditary predisposition, 5172
 Herpes zoster, 3623
 Hexokinase, 1015
 HGF, 6134
 High content analysis (HCA), 1154
 High content screening, 1406
 High-density inhomogeneities, 2019
 High-dose alkylating chemotherapy, 267
 High-dose chemotherapy, 7111
 High-dose doxorubicin-ifosfamide therapy, 9424
 High-dose-rate brachytherapy, 285, 7035
 High-dose treatment, 102
 High gene copy number, 9066
 High-grade gliomas, 200, 2003, 8753
 High-grade malignant gliomas, 8729
 High-intensity focused ultrasound, 109, 3631
 High-precision radiotherapy, 2002, 6533
 High-risk colon cancer, 6116, 6117
 High-risk factors in colon cancer, 6030
 High-risk prostate cancer, 7030
 High-risk screening, 224
 High-risk thyroid cancer, 8555
 Hindgut, 6101
 Hippocampus, 8705
 Hispanic population, 5048
 Histological subtypes, 5017
 Histological subtyping, 1447
 Histone deacetylase, 1121
 Histone deacetylase inhibitors, 1001, 1122, 6104, 9208
 Histopathology, 5117
 HIV, 9218
 HNF4a, 6615
 HNPCC, 1456
 HNSCC, 388, 8545
 Hodgkin's lymphoma, 55, 56, 57, 99, 2052, 2105, 4206, 9221, 9225, 9231
 Home-based cancer care, 4174
 Home-based chemotherapy, 4151
 Home enteral nutrition, 3064
 Home vare, 4240
 Homogeneity index, 2050
 Hormonal receptor, 5024
 Hormonal therapy, 5018
 Hormone-receptor positive breast cancer, 5086
 Hormone receptors, 396, 1464, 5046, 5100
 Hormone resistance, 5005
 Hormone-resistant prostate cancer, 7045
 Hospital admissions, 5154
 Hospital care, 3014
 Hospital volume, 6069, 6503
 HOXB13, 7019
 HOXB9, 1445
 HPV, 8500, 8591
 HPV-16/HPV-18, 8047
 HPV infection, 8024, 8535
 HPV vaccination, 52
 Human acellular dermal matrix, 6085
 Human papilloma virus, 53, 8522, 8557
 Human telomerase, 8009
 Hyaluronan, 5027
 5-Hydroxyindoleacetic acid, 6564
 Hyperalgesia, 3016

- Hyperbaric oxygen, 8569
- Hypercalcemia of malignancy, 3051
- Hyperglycemia, 9228
- Hypericin, 1231
- Hyperlipidemia, 7148
- Hypersensitivity, 1302
- Hypertension, 1412, 6093
- Hyperthermia, 1045, 1151, 5033, 9417
- Hyperthermic intraperitoneal chemotherapy, 30, 2505, 6072, 6074
- Hypofractionated prophylactic radiotherapy, 9054
- Hypofractionated stereotactic radiotherapy, 8727
- Hypofractionation, 2060, 4118, 5127, 7026, 7036, 7038, 8738
- Hypogonadism, 4135, 7171
- Hypomagnesemia, 6095
- Hyponatremia, 1461
- Hypoxia, 16, 19, 111, 113, 114, 206, 255, 1160, 1163, 1410
- Hypoxia-inducible factor-1 (HIF-1), 121
- Hypoxia-inducible factor-1 α (HIF-1 α), 8720
- Hypoxia inducible factor (HIF), 7156
- Hypoxic antitlastic stop-flow pelvic perfusion, 6034
- Hypusine, 1241
- Hysterectomy, 4207
- Idarubicin, 1223
- IDH, 1
- Idiopathic interstitial pneumonias, 9107
- IGF, 278, 1113, 6063
- IGF, during human development, 278
- IGF, functions, 278
- IGF-1, 6514
- IGF-1 gene polymorphism, 1090
- IGF-1R, 277, 1242, 9013, 9143
- IGF-1R inhibitors, 187
- IGFBP3, 9143
- IHC/FISH, 5189
- IHQ, 1464
- Illness trajectory, 8759
- Image-based interstitial brachytherapy, 2048
- Image guidance, 8560
- Image-guided adaptive brachytherapy, 297
- Image-guided drug delivery, 27
- Image guided radiotherapy (IGRT), 2051, 2061
- Image-guided radiotherapy (IGRT), 110, 2013, 2015, 2159, 3038, 7010, 8574, 9041
- Image-guided surgery, 2500
- Image registration, 2016
- Imaging, 16, 71, 113, 235, 2109, 4101, 5148, 5202, 7109, 8597, 9431
- Imatinib, 9233, 9404, 9413
- Imatinib mesylate, 2509
- Immediate breast reconstruction, 2503, 5141, 5142
- Immigration, 3537
- Immortal time bias, 1303
- Immune modulation, 9135
- Immune regulation, 89
- Immune responses, 7012
- Immune therapy, 6602
- Immunogenicity, 8047
- Immunoglobulin, 97
- Immunoglobulin levels, 9235
- Immunohistochemical detection, 6023
- Immunohistochemistry, 194, 1428, 1450, 5101, 5178, 9002, 9025
- Immunomodulators, 6149
- Immunosuppression, 1080
- Immunotherapy, 59, 60, 89, 91, 353, 1107, 1109, 1253, 6146, 7046, 7135, 9079, 9305
- Impact of living with a PEG, 80
- Improving outcome, 155
- In silico simulations methods, 1071
- In vitro studies, 1214, 1218
- Incidence, 3524, 4134, 7102, 8535
- Incidence and mortality, 7100
- Incidents, 4225
- Incontinence, 6163
- Incremental medical costs, 3623
- Indications for sentinel node biopsy in breast cancer, 5136
- Individual internal gross tumor volume, 2056
- Indocyanine green, 5009, 5152
- Induction chemotherapy, 8511, 8528, 8530, 8533, 8538, 8545, 8546, 8549, 8550, 8586, 9033
- Induction erlotinib therapy, 9035
- Induction therapy, 9020
- Infections, 1436, 4275
- Infertility, 150
- Infiltrating lobular carcinoma, 5111
- Inflammation, 1123, 1124, 5179, 6510, 7018, 9140
- Inflammatory breast cancer, 5077
- Inflammatory cytokines, 4027
- Inflammatory status, 1439
- Informal caregivers, 4212, 4215
- Information needs, of paediatric patient's parents, 4214
- Information needs, of patients, 3023, 3643, 4184
- Information resources, 5186
- Information seeking behaviour, 4203
- Informed choice, 4209
- Informed Consent Form, 1311
- Infrared microspectroscopy, 2156
- Infusion time, 3625
- Inhibitors of Apoptosis proteins (IAPs), 354, 1044, 1213
- Inhomogeneity, 2019
- Iniparib, 5025, 9006
- Initial staging, 250
- INK4a, 1003
- Innovations, 9
- Inoperability, 403
- Inoperable gastric cancer, 6543
- Inpatient chemotherapy, 4271
- Inquiring about sexual orientation, 152
- Insomnia, 3026
- Instability, 5024
- Insurance, 3610
- Integrated care pathway, 3638
- Integrins, 418, 1069, 8526
- Intensity-modulated radiotherapy (IMRT), 256, 6055, 7030, 7032, 8540, 8550, 8552, 8555, 8560, 8568, 8717
- Intensity-modulated radiotherapy (IMRT), with IGRT vs IRRT, 2022
- Intercostobrachial nerve, 5151
- Interferon gamma, 1159, 2165
- Interfraction motion during radiotherapy, 2015
- Interfractional variation, 2009, 8576
- Interim analysis, 2163
- Interleukin-2, 7135
- Interleukin-6, 1066
- Intermittent oxaliplatin, 6098
- Intermittent pneumatic compression, 3074
- Internal gross tumor volume, 2027
- Internal mammary vessels, 5115
- Internal margins, 8019
- Internal Target Volume (ITV), 2007, 2065, 2068, 6535, 9052
- International auditing, 6000
- International variations, 6501
- Internet, 2154, 4159

- Interprofessional research, 193
 Interstitial brachytherapy, 5125
 Interstitial lung disease, 1308
 Interventions, 7, 324, 3014
 Interviews, 4214
 Intestinal obstruction, 6087
 Intestinal resection, 2042
 Intra-arterial fluorescence diagnostics, 8603
 Intrabeam®, 5118
 Intracellular transfer, 1044
 Intracerebral arteriovenous malformation, 8739
 Intracranial lesions, 4124
 Intracranial meningioma, 8723
 Intrafraction motion, 2061
 Intraoperative analysis, 5146
 Intraoperative radiotherapy, 5195, 6540
 Intraoperative sentinel lymph node analysis, 5010
 Intraoperative ultrasonography, 5143
 Intraoperative ultrasound, 9055
 Intraperitoneal chemohyperthermia, 29
 Intraperitoneal chemotherapy, 31, 2510, 6523, 8013
 Intraperitoneal infusion, 8032
 Intratumoral boost, 9048
 Intravenous iron, 3000
 Invasion, 418, 8011
 Invasive lobular carcinoma, 5018
 Ionisation Chamber Array, 2025
 Ionizing radiation, 35, 2010
 iPad, 2501
 Ipilimumab, 9306, 9317, 9318, 9322
 Ipsilateral neck irradiation, 8573
 Iran, 3526
 Irinotecan, 6007, 6094, 6097, 9102, 9104
 Irradiation, 1081, 2030
 Isolated limb perfusion, 9403
 Italian survey, 2070
 Ixabepilone, 9080

 JAK2 tyrosine kinase, 9203
 Japanese patients with advanced solid tumours, 1236
 JCV T-antigen, 6625
 JNJ-26481585, 1234
 Job stress, 3642

 Karnofsky performance status, 4223
 Keratoacanthoma, 130
 Ketamine, 1225
 Ki-67, 5113, 6557, 9436
 Kidney cancer, 70, 7143, 7154
 Kidney function, 7057
 Kidney neoplasms, 7139
 Kinase inhibitor, 129
 Klatskin tumours, 290, 6533
 Knockdown, 2030
 Knowledge test for breast cancer patients, 4213
 Kocher's incision, 6081
 KORTUC, 5020
 KRAS-BRAF, 6020
 KRAS gene, 1101, 6041, 6088, 6095, 6128, 6131, 6135, 6137, 6141, 6143
 KRAS gene, mutations, 1143, 1434, 1455, 6065, 6090, 6109, 6122, 6138, 9093
 KRAS gene, mutations, test, 9150
 KRAS-mutated tumours, 6091
 KRAS mutational status, 6136
 KRAS p.G13D, 6014
 KRAS wild type, 6144

 L-Asparaginase, 1313
 Lactate, 1004
 Lactic acid export, 121
 Laminin-5, 8527
 Lanreotide, 6630
 Lantadene, 9311
 Laparoscopic surgery, 2509, 2516
 Laparoscopy, 2511, 6554
 Lapatinib, 1222, 1247, 5050, 5061, 5065, 5069, 8742
 Lapatinib resistance, 1049
 LAR, 6634
 Large rearrangements, 1130
 Laryngeal cancer, 8525, 8561, 8582
 Laryngeal carcinoma, 8526
 Laryngeal neoplasm, 8556
 Laryngectomy, 8583
 Laryngo-esophageal dysfunction-free survival, 8567
 Laser microdissection, 9133
 Laser particle acceleration, 282, 2006
 Laser radiotherapy, 2006
 Late effects, 23, 78, 6018
 Late functional outcome, 42
 Late skin damage, 2040
 Late toxicities, 41, 7040
 Latissimus dorsi flap, 2503
 Lats2 tumour suppressor, 229
 Learning curve, 4230
 Learning phase, 5143
 Lectin-array, 1460
 Lectins, 1239
 Legislation, 3519
 Leiomyosarcoma, 9402
 Lenalidomide, 9200
 Leptin, 9067
 Letrozole, 5016
 Leucovorin, 6118
 Leukaemia, 1026, 1059, 4211
 Level 3 nodes, 5144
 LH, 7112
 LHRH receptor, 7043
 Life expectancy, 2515
 Limb-sparing surgery, 9416
 Limited stage, 9036
 Linifanib, 9120
 Lipid raft, 9309
 Liposomal anthracycline, 5056
 Liposomal doxorubicin, 1257, 5075
 Liposome-encapsulated hemoglobin, 1088
 Liposomes, 27, 1219
 Lived experiences of women with exulcerated breast carcinoma, 4158
 Liver, 2157, 2507, 6638, 9304
 Liver abscess, 6086
 Liver cancer, 2007
 Liver cirrhosis, 3059
 Liver-first approach, 6061
 Liver function, 7055
 Liver index, 6156
 Liver metastases, 319, 406, 2151, 2500, 5100, 6009, 6011, 6040, 6061, 6067, 6077, 6134, 6534
 Liver neoplasm, 6538
 Liver regeneration, 6073
 Liver resection, 6048, 6077, 6546
 Liver tumour, 6530
 Local control, 8726
 Local control rate, 2044
 Local control rate and survival rate, 8517

- Local failure, 6531
- Local recurrence, 337, 6060, 6629
- Local relapse, 314
- Locally advanced breast cancer, 5046
- Locally advanced head and neck cancer, 8511, 8538
- Locally advanced lung cancer, 256, 4011
- Locally advanced nasopharyngeal carcinoma, 8548
- Locally advanced NSCLC, 9058
- Locally advanced NSCLC, stage III, 9037
- Locally advanced rectal cancer, 6008, 6031, 6037, 6061
- Locally advanced SCCHN, 8607
- Locoregional control, 5130
- Locoregional recurrence, 315, 5142
- Long-acting filgrastim, 1215, 1216
- Long-standing goitres, 8596
- Long-term care, 20
- Long-term chemotherapy, 9110
- Long-term complications, 20
- Long-term effects, 4133
- Long-term excess mortality in NSCLC, 9022
- Long-term follow-up, 24, 6147, 8722
- Long-term outcome, 8604
- Long-term overall survival, 1006
- Long-term results, 5008, 5130, 8021
- Long-term safety, 7008
- Long-term survivors, 6161
- Long-term survivors of cancer, 4253
- Long-term survivors of childhood cancer, 21
- Long-term toxicity, 8541
- Long-term use, 3060
- Longitudinal design, 1085
- Loss of heterozygosity, 8525
- Low anterior resection, 6163
- Low-dose CRT, 6058
- Low dose paclitaxel as a radiosensitiser, 8579
- Low dose rate, 285
- Low-dose X-ray, 2031
- Low-grade gliomas, 4100, 8719
- Low rectal cancer, 6001, 6012, 6043, 6062
- Low-voltage electric pulses, 1089
- ¹⁷⁷Lu-DOTA-octreotate, 6101
- Luminal B breast cancer, 5113
- Luminal breast cancer, 5175
- Luminex, 1142
- Lung adenocarcinoma, 1455, 9071
- Lung adenocarcinoma stage I, 1098
- Lung cancer, 67, 186, 187, 188, 257, 347, 404, 1032, 1042, 1072, 1087, 1091, 1100, 1102, 1137, 1203, 1424, 1442, 2065, 2066, 2107, 2157, 2158, 3503, 3504, 3527, 3529, 4002, 4209, 4232, 4237, 4251, 4257, 4263, 4264, 9005, 9011, 9014, 9018, 9021, 9022, 9026, 9031, 9034, 9038, 9041, 9042, 9051, 9052, 9063, 9065, 9068, 9078, 9079, 9082, 9098, 9107, 9130, 9131, 9148
- Lung carcinoma, 8564
- Lung fibrosis, 2004
- Lung metastases, 6039
- Lung motions, 9040
- Lung NET, 6572
- Lung segmentectomy, 2501
- Lung toxicity, 9046
- Lung ventilation, 2039
- Lymph node, 2109, 8017
- Lymph node delineation, 8576
- Lymph node dissection, 212, 5133, 6551
- Lymph node metastasis, 6625, 9068
- Lymph node ratio, 6053, 6557
- Lymphadenectomy, 153
- Lymphangiogenesis, 1062
- Lymphoblastic leukaemia, 9206, 9214
- Lymphoblastic lymphoma, 4110
- Lymphoedema, 293, 295, 3074, 4238
- Lymphoedema management, 294
- Lymphomas, 55, 97, 236, 7171, 9201, 9208, 9219, 9228
- Lymphopenia, 8038
- Lynch syndrome, 6035, 6045
- Lysyl tRNA synthetase, 1043
- Lytic peptides, 1211
- M30, 6610
- M65, 6610
- Macrodissection, 1142
- Macrophages, 120, 1068
- Maggie's Centres, 265
- Magnetic resonance, 3018, 5193
- Magnetic resonance guidance, 109
- Magnetic resonance imaging, 62, 106, 110, 162, 280, 2102, 4014, 5196, 9431
- Magnetic resonance spectroscopy, 4104
- Maintenance treatment, 400, 6124, 9005, 9058, 9072, 9083, 9086
- Major surgery, 6162
- Male breast cancer, 5168
- Malignancy, 8596, 9411
- Malignant ascites, 1094, 1112, 3004, 3080, 6092
- Malignant brain tumors, 4126
- Malignant fibrous histiocytoma, 9410
- Malignant fungating wound, 4158
- Malignant glioma, 8715
- Malignant melanoma, 1403, 9310, 9329
- Malignant pleural mesothelioma, 1157, 1158, 9024, 9027, 9032
- Malignant salivary gland tumors, 84
- Malnutrition, 3064, 4273
- MALT, 9232
- Mammalian target of rapamycin (mTOR), 248, 1034, 1070, 1114, 1155, 1157, 8709, 9205
- Mammograms, 5134
- Mammographic density, 3513
- Mammography, 3538
- Managed clinical network, 3601
- Management, 295, 5138, 6036
- Manganese superoxide dismutase, 1048
- Mantle cell lymphoma, 9211, 9212, 9213
- Manual lymphatic drainage, 3074
- Manuscript writing/reviewing, 233
- MAPK, 1155, 7159
- Marginal zone lymphoma, 9240
- Margins, 2059
- Marker, 1096
- Markov model, 3612
- MASCC score, 3045, 3047
- Mass spectrometry, 139
- Mastectomy, 2512, 4254, 5149
- Maternal cancer, 4
- Matrix metalloproteinase 9, 8526
- Matrix metalloproteinases, 1137
- Mature outcome, 6058
- Maxillary sinus, 8566, 8581
- Maximal removal, 8741
- Maximum intensity projection, 2066
- mCRC, 6005, 6155
- mCRPC, 7013
- MCTs, 121
- MDGA1 expression, 6026
- Mdm2, 1060
- MdmX, 1060

- MDR1, 9023
Meaning in illness, 4195
Mechanism, 1242
Mechano-transduction, 6028
Mediastinal irradiation, 9221
Mediastinal lymph nodes, 2054
Mediastinal lymphadenopathy, 1308
Mediastinal tumor, 4110
Medical audit, 6070
Medical care services, 4275
Medulloblastoma, 4120, 4134, 8725, 8748
MEK, 1156
MEK inhibitor, 384, 1249
Melanin, 1078
Melanoma, 46, 47, 91, 127, 128, 129, 330, 1077, 1078, 1097, 1233, 1452, 2506, 3505, 9301, 9302, 9303, 9304, 9305, 9306, 9307, 9308, 9309, 9312, 9313, 9315, 9316, 9317, 9318, 9323, 9324, 9327, 9328, 9333
Melanoma therapies, 385
Melfalan, 9200
Membrane disruption, 1211
Menatetrenone, 6594
Meningioma, 8709, 8722, 8730
Mental health, 3642
Mercaptopurine, 9239
Merck, 356
Mesenchymal stem cells, 1064
Mesothelioma, 1168, 9039
Met, 1055
MET amplification, 8005
Meta-analysis, 114, 6153, 7039, 7164, 9053, 9081
Meta-regression, 3509
Metabolic syndrome, 3063
Metabolism, 1
Metabolomics, 1071, 1099
Metal artifact, 8577
Metallic wedge, 2025
Metalloproteinase, 417
Metastasis, 47, 122, 416, 1054, 1066, 1071, 3504, 4012, 4136, 4170, 5002, 5050, 5057, 5062, 6006, 6064, 6516, 6621, 7048, 8033, 8593, 8758, 9325
Metastectomy, 6039
Metastatic bone tumour, 9117
Metastatic breast cancer, 3604, 5000, 5001, 5006, 5026, 5045, 5051, 5056, 5064, 5069, 5070, 5071, 5075, 5076, 5079, 5088, 5093
Metastatic castration-resistant prostate cancer (mCRPC), 7049, 7052, 7060, 7061
Metastatic colorectal cancer (mCRC), 400, 4007, 6003, 6004, 6015, 6016, 6088, 6091, 6096, 6105, 6112, 6113, 6127, 6149, 6150, 6152, 6162
Metastatic disease, 396, 7144
Metastatic lung cancer, 9066, 9069, 9141, 9152
Metastatic melanoma, 1029, 4021, 9320, 9321
Metastatic NSCLC, 4023, 9077
Metastatic pleural nodule, 9071
Metastatic relapse, 398
Metastatic renal cancer, 4018
Metastatic renal cell cancer, 1401
Metastatic renal cell carcinoma, 1006, 1139, 7134, 7152
Metastatic sites, 6612
Metastatic soft tissue sarcoma, 9426
Metastatic solid tumors, 5067
Metasynthesis, 4249
Metformin, 336, 5114
Methotrexate, 1082, 4106, 4111, 4113, 5059, 5199
Methoxyflurane, 3058
Methylation, 1035, 1037, 1039, 1120, 1421, 9214
Methylation-specific PCR, 1038
Metrics for validation registration methods, 2034
Metronomic chemotherapy, 1115
MFH, 9409
mFOLFOX7, 6098
MGMT promoter methylation, 9429
MGN1703, 6149
MHC class II, 9309
MIB-1, 1448
Microarrays, 199, 346
Microenvironment, 97, 206
Microfluidic biochips, 205
Microfluidic chip, 5110
Micrometastases, 4108, 5014, 5110
Micrometastatic spread of cancer cells, 303
Microparticles, 3075
MicroRNA, 12, 1052, 1103, 1409, 5007, 7160, 8595, 9324
MicroRNA dysregulation, 13
MicroRNA expression, 1051, 1100
MicroRNA regulation, 1042
Microsatellite instability, 178, 8525
Microscopic disease, 75
Microtubule, 1022
Microvascular reconstructions, 168
Microwave, 2502
Middle and lower bile duct carcinoma, 1425, 6553
Middle face reconstruction, 168
Midwife, 8053
Mifamurtide, 9428
Mina53, 1442
Minimal residual disease, 9063
Mismatch repair, 1452
Mitochondria, 9409
Mitochondrial point mutations, 1162
Mitotic catastrophe, 1018
MLH1 methylation and MSI, 1456
MMP, 1067
MMR genes, 1456
Molecular analysis, 801
Molecular breast cancer subtypes, 1449
Molecular diagnostics, 1403, 1427
Molecular factors, 6635
Molecular imaging, 234, 236
Molecular mechanisms., 1227
Molecular micrometastases in sentinel node, 5010
Molecular subtype, 1451
Molecular target, 379
Molecular targeting agents, 84, 328, 1232, 1260, 6100
Molecular targeting therapy, 81, 149, 5028, 5029
Monocarboxylate transporter, 1004
Monoclonal antibody, 1201, 1226, 1317, 3617, 7013
Monotherapy, 3000
Morbidity, 8553
Mortality, 7102
Motility, 416
Mouse models, 1009
Mouse models, BRCA1-associated breast cancer, 381
MPI, 4127
mRCC, 1400, 7149, 7150
MRD, 4114
MRP1, 9023
^{99m}Tc-NTP 15-5 radiotracer, 9435
MTHFR gene, 4109
mTOR, 248, 1034, 1070, 1114, 1155, 1157, 8709, 9205
mTOR inhibition, 7152
mTOR inhibitors, 5005, 7054, 7137, 7147, 7148

- Mucin expression, 6611
 Mucinous adenocarcinomas, 6016
 Mucosal malignant melanoma, 8600
 Mucosal melanoma, 9330
 Mucositis, 3067, 4273, 4274
 Multi-gene assay, 5161
 Multi-gene tests, 5165
 Multi-targeted kinase inhibitor, 1251, 1419
 Multicentric breast cancer, 5130
 Multicentric experience with Ipilimumab, 9317
 Multicentric occurrence, 6594
 Multidisciplinary approach, 185, 3609, 4010, 4153, 4173, 6036, 9402
 Multidisciplinary management, 245, 7021
 Multidisciplinary team (MDT), 3618
 Multidrug resistance, 1145
 Multikinase inhibitor, 6576, 7141
 Multimodality treatment, 65, 66, 155, 414, 2160, 6034, 6126, 6130
 Multiple liver metastasis, 6080
 Multiple myeloma, 9202, 9216, 9227, 9238
 Multiple primary cancers, 3507, 3535
 Multiplexing, 194
 Muscle invasive bladder cancer, 2103
 Muscle wasting, 7158
 Mutation, 133, 1149, 1162, 6606, 6632, 7159, 9018
 Mutation frequency, 9138
 Mutational polymorphism, 1101
 MVCT, 2017
 Mycosis fungoides, 1458, 9315
 Myelodysplastic syndrome, 8748
 Myeloid cell, 6142
 Myeloid-derived suppressor cells, 36, 9130
 Myeloma bone disease, 9220
 MYH-associated polyposis, 7120

 N-Acetyltransferase, 7119
 Nanocapsules, 25
 Nanoparticles, 1223, 1224, 2001
 Nasal cavity, 8578
 Nasopharyngeal cancer, 8542, 8558, 8575, 8586
 Nasopharyngeal carcinoma, 2008, 8550, 8565, 8599, 8604
 Nasopharynx, 8554
 National cohort, 6539
 National Plan, 3611
 Natural killer cells, 5004, 5108
 Nausea, 4270, 4273
 Nausea and vomiting, 3048
 Near-infrared fluorescence, 5009
 Near-infrared fluorescence imaging, 2500
 Necrosis, 1231
 Neoadjuvant chemoradiotherapy, 6037, 6043, 6049, 6059, 6518
 Neoadjuvant chemotherapy, 2106, 5052, 5063, 5068, 5115, 5156, 5164, 5196, 8741, 9027
 Neoadjuvant hormonal therapy, 7030
 Neoadjuvant treatment, 319, 4019, 4252, 5043, 5159, 5176, 6047, 6064, 6522
 Neoplasms, 1314
 Neoplastic meningitis, 8757
 Neopterin, 4223
 Nephrotoxicity, 3078
 Neratinib, 5066, 5067
 Network Focused Nursing, 51, 4221
 Network meetings, 4260
 Network of Excellence, 171, 172
 Networking, 4258
 Neuroblastoma, 102, 4105, 4108, 4114, 4132
 Neurocognitive impairment, 8705
 Neuroendocrine carcinoma, 6604, 9332
 Neuroendocrine disease, 1104, 6516
 Neuroendocrine tumours (NETs), 6554, 6561, 6564, 6566, 6569, 6571, 6572, 6581, 6598, 6605, 6616, 6618, 6619, 6620, 6628, 6630, 6634, 9097
 Neuroendocrine tumours (NETs), metastases of, 6621
 Neurology, 240
 Neuropathy, 3017, 6164
 Neurotoxicity, 6089, 6147
 Neutropenia, 3511, 4025, 9225
 Neutrophil gelatinase-associated lipocalin, 8523
 Neutrophil-to-lymphocyte ratio, 1418, 1425, 1439, 1443
 New drugs, 1168
 Next-generation sequencing, 800
 NF- κ B, 1012
 NF- κ B, 1046, 1047, 1133, 1153, 6614, 9142, 9232
 NF- κ B alternative pathway, 1153
 NGR-hTNF, 1205, 8030, 9014, 9103
 NHE1, 1069
 Nigella sativa oil, 1082
 Nimotuzumab, 8588, 9124
 NKX3.1, 1124
 NKX-2 gene, 4122
 Nomogram, 5021
 Non-adherence, 5162
 Non-coding RNA, 14
 Non-endemic population, 8542
 Non-hematologic malignancies, 1210
 Non-Hodgkin's lymphoma, 103, 3515, 9243
 Non-inferiority trials, 1300
 Non-interventional study, 5072, 5073, 7151
 Non-melanoma skin cancer, 9314
 Non-muscle invasive bladder cancer, 7118
 Non-profit screening campaign in Uganda, 3639
 Non-sarcoma paediatric malignancies, 277
 Non small cell carcinoma, 1121
 Non small cell lung cancer (NSCLC), 65, 66, 255, 268, 301, 327, 404, 1025, 1039, 1096, 1143, 1153, 1208, 1408, 1422, 1434, 1446, 2106, 3029, 3030, 3638, 4001, 4024, 9003, 9006, 9008, 9012, 9013, 9025, 9029, 9030, 9033, 9035, 9043, 9044, 9045, 9048, 9050, 9053, 9055, 9056, 9057, 9058, 9059, 9060, 9062, 9067, 9075, 9080, 9083, 9084, 9085, 9086, 9088, 9091, 9092, 9094, 9096, 9099, 9100, 9101, 9106, 9108, 9109, 9110, 9111, 9112, 9115, 9116, 9117, 9119, 9120, 9124, 9126, 9127, 9129, 9132, 9134, 9135, 9138, 9139, 9143, 9147, 9150
 Non small cell lung cancer (NSCLC), radiotherapy, 2054
 Non-small-cell lung cancer (NSCLC), radiotherapy, 2026
 Non small cell lung carcinoma, 1007
 Non-smokers, 9116
 Non-squamous non small cell lung cancer, 9076, 9128
 Non-surgical approach, 8578
 Nonseminoma, 7142
 Normal tissue, 5, 7
 Normal tissue damage, 6
 Normal tissue responses, 1136
 Normal tissue toxicity, 2038
 Northeastern part of Thailand, 3500
 Novel agents, 9220
 NSCLC, see Non small cell lung cancer
 Number of treatment lines, 9077
 Nurse, 4241, 8053
 Nurse administration, 4267
 Nurse education, 4273
 Nurse-led clinic, 4182, 4184
 Nurse-led services, 4183, 4187

- Nurse sensitive outcome indicators, 4157
 Nurses experience, 4243
 Nursing, 324, 361, 4157, 4201, 4208, 4233, 4244, 4248
 Nursing approach, 4226
 Nursing consult, 4185, 4224
 Nursing development, 4222
 Nursing guidelines, 4175
 Nursing management, 117
 Nursing roles, 4186, 4230
 Nursing sensitive outcomes, 4155, 4219
 Nutrition, 166, 4164, 4262
 Nutritional practices, 3046
 Nutritional supplement, 9145

 O6-Methylguanine DNA methyltransferase, 1129
 Obesity, 334, 2009, 4013
 Obliteration, 8739
 Observational studies, 3007, 3620, 9401
 Occult neuroendocrine tumours, 6554
 Octreotide, 6566, 6571
 Office-based medical oncology, 3630
 Olaparib, 381, 1257
 Older adult, 4212
 Older patients, 1255, 4004, 4017, 4033, 4034, 5133, 5135, 6555
 Oligometastases of the brain, 8727
 Oman, 1451
 Omega-3 desaturase, 1033
 Omentum, 6079
 On-board image (OBI) guidance, 7023
 Onco-technology, 2153
 Oncogene, 338
 Oncogenic BRAF, 127, 385
 Oncogenic mutation, 9307
 Oncogenic RAS, 127, 385
 Oncogeriatric cancer, 6563
 Oncogeriatrics, 219
 Oncology, 1300, 3618, 3636, 4183, 4244
 Oncology nurses, 4193
 Oncology nursing, 4174
 Oncology nursing and primary nursing care in cancer, 4029
 Oncology Nursing Minimum Data Set (ONMDS), 4155, 4219
 Oncology nursing research, 4222
 Oncology patients, 4162
 Oncology pharmaceuticals, 1312
 Oncology pharmacists, 3078
 Oncolytic medication, 4217
 Oncolytic virotherapy, 9403
 Oncolytic virus, 1109, 1258, 9323
 Oncoplastic flap reconstruction, 2504
 Oncotype DX Recurrence Score, 1420, 5165
 One-step nucleic acid amplification (OSNA), 5146
 One-step nucleic acid amplification (OSNA) assay, 5145
 Online searching, 3643
 ONX 0912, 1209
 Oophorectomy, 2511
 Open innovation space, 349
 Open source eCFR system, 2162
 Operable breast cancer in premenopausal women, 5198
 Opioid rotation, 3016
 Opioids, 342, 3011
 Optical guidance biopsy, 2150
 Optical spectroscopy, 2151
 Oral and oropharyngeal cancer, 8541
 Oral cancer, 8523, 8524, 8569, 8593, 8595, 8598, 8601, 8603, 8605
 Oral cancer, sentinel lymph node biopsy, 8506
 Oral carcinoma, 8571

 Oral chemotherapy, 242, 1316, 4178
 Oral cytotoxic therapy, 243
 Oral drug therapy, 241
 Oral fluoropyrimidines, 6059
 Oral medication, 4217
 Oral mucositis, 4265
 Oral sex, 8522
 Oral squamous cell carcinoma, 8520
 Oral vinorelbine, 4023, 5071
 Orbital oncopathology, 8581
 Organ-intact treatment, 8582
 Organ motion, 2038
 Organ preservation, 2041, 7126, 8567
 Organoid culture, 1161
 Origins of ovarian cancer, 376
 Oropharyngeal cancer, 4265, 8500, 8540, 8557
 Oropharyngeal squamous cell carcinoma, 8514
 Osteopontin, 6029, 8720
 Osteoporosis, 117
 Osteosarcoma, 4111, 4136, 5102, 9423, 9427, 9428
 Outcome, 317, 318, 3616, 6030, 6546, 6629, 7170, 8508, 8706, 9146, 9437
 Outcome prediction, 99
 Outpatient development, 4154
 Ovarian cancer, 378, 379, 1021, 1152, 3601, 8003, 8006, 8007, 8029, 8030, 8034, 8035, 8036, 8038, 8039, 8040, 8046, 8048, 8051
 Ovarian cancer immune escape, 8008
 Ovarian cancer stem cells, 8011
 Ovarian carcinoma, 1061, 1134, 8013
 Ovarian germ cell tumours, 4130
 Ovarian removal, 8026
 Ovary, 376, 8006
 Overall survival, 164, 1301, 2042, 3607, 5042, 5060, 6160, 6569, 6639, 7163, 8031
 Oxaliplatin, 1229, 6003, 6004, 6048, 6049, 6089, 6092, 6100, 6118, 6132, 6147, 6156, 6164, 6593
 Oxaliplatin and capecitabine for untreated advanced, 6584
 Oxaliplatin peripheral neuropathy, 3041
 Oxidative stress, 1014, 1082, 2045, 8005
 Oxygen-sensing pathways, 111

 p16, 1030, 8505
 p21, 8045
 p53, 131, 229, 1024, 1034, 6137, 6608
 P-Glycoprotein, 1013, 1044
 Paclitaxel, 1207, 1218, 1308, 6579, 6586, 6600, 8513
 Paclitaxel and capecitabine, 8587
 Paediatric ALL, 9205
 Paediatric and adult cancers, 3067
 Paediatric brain tumour, 4129
 Paediatric malignancies, 353, 9201
 Paediatric oncology, 171, 172, 173, 4121, 4126
 Paediatric PK/PD, 9428
 Paediatric radio-oncology, 4131
 Pain, 190, 191, 192, 3026, 4173, 7004
 Pain Intensity Difference, 3057
 Pain management, 4177
 Pain reduction, 3062
 pAKT, 9232
 PALB2, 1131
 Palladium(II) complex, 1212
 Palliation, 323, 2515
 Palliative and analgesic response, 7016
 Palliative care, 11, 409, 410, 3003, 3022, 3611, 3637, 3645, 4150, 4180, 4234, 4235, 4239, 4240
 Palliative care services, 3611

- Palliative chemotherapy, 3621
- Palliative Prognostic Index, 3021
- Palliative radiotherapy, 192
- Palliative surgery, 5042
- Palonosetron, 3056, 3065, 3079
- Pamphlets analysis, 1312
- Pancreas, 6525
- Pancreatic cancer, 803, 1233, 6506, 6510, 6511, 6524, 6532, 6540, 6556, 6568, 6577, 6587, 6588, 6589, 6591, 6599, 6613, 6632, 6636
- Pancreatic duct, 2514
- Pancreatic endocrine tumour, 6557
- Pancreatic neuroendocrine tumours, 6561, 6573
- Pancreatic remnant, 2514
- Pancreatic resection, 4010
- Pancreatoblastoma, 105
- Pancreatoduodenectomy, 2513, 2514, 6547
- Pancytopenia, 8748
- Panitumumab, 6007, 6095, 6096, 6123, 6132, 6143, 6155
- Papillary or chromophobe renal cell carcinoma, 7137
- Papillary thyroid carcinoma, 1079
- Para-aortic nodes, 8016
- PARAMOUNT trial, 9072
- Paranasal sinus cancer, 8528
- Paraneoplastic neurological syndromes, 240
- Parathormone, 8584
- Parental cancer, 3081, 4196
- Parents of children with cancer, 4203, 4214
- Parotid gland, 4129, 8575
- Paroxetine, 3020
- PARP, 1257
- PARP-1, 5177
- Partial breast irradiation, 364, 365, 366, 367
- Partial least squares analysis, 1099
- Partial nephrectomy, 213
- Participation in psychosocial care programs, 4166
- Pathobiology, 1042
- Pathogenesis, 13, 99
- Pathological characteristics, 1127
- Pathological complete response, 5159, 5176
- Pathological fracture, 3061
- Patient and relatives, 4208
- Patient aspects, 185, 244, 3626, 3633, 4220, 8758
- Patient care, 38, 4188
- Patient characteristics, 9331
- Patient communication, 2154
- Patient education, 242, 4192
- Patient experience, 11
- Patient preference, 4151
- Patient-reported outcome, 3005, 3029, 4232, 5086, 7001, 7015, 8028, 8029
- Patient reported survey, 5088
- Patient safety, 8025
- Patient satisfaction, 4184
- Patient-caregiver dyads, 4272
- Pattern of recurrence, 8543
- Payment strategies, 3608
- Pazopanib, 1207, 1250, 1404, 7157
- PDGF receptor, 2165, 6139
- Pd(II) and Pt(II) polyamine complexes, 5092
- PEG, 80
- Pegfilgrastim, 5167
- Pelvic exenteration, 6078, 6079
- Pelvic lymph nodes, 2059
- Pelvic radiation damage, 8022
- Pemetrexed, 9060, 9072, 9078, 9083, 9106, 9109, 9118, 9128, 9133
- Penile cancer, 34, 7110, 7146
- Penile carcinoma, 33
- People affected by cancer, 3643
- Peptide, 1219
- Peptide vaccine, 1107
- Perceived stress, 6159
- Performance-based agreement oncology, 45
- Performance evaluation, 3622
- Performance status, 4033
- Performance status 3, 9125
- Perineal pseudocontinent colostomy, 6062
- Perioperative chemotherapy, 6528, 6562
- Perioperative complication, 4004
- Periorbital cancer, 9334
- Peripheral blood lymphocytes, 1039
- Peripheral blood tumour cells, 5090
- Peripheral neuropathies, 118, 1229
- Peripheral stem cell transplantation, 9230
- Peritoneal carcinomatosis, 29, 6072
- Peritoneal cytology, 6076
- Peritoneal mesothelioma, 30
- Peritonitis, 1436
- Peritumoral edema, 2067
- Permeability, 2003
- Peroxisome proliferator-activated receptor gamma, 1048
- Persistence, tamoxifen treatment, 5169
- Persistence, trastuzumab treatment, 5160
- Persistent pain, 5195
- Personalised breast cancer therapy, 228
- Personalised chemotherapy, 3615
- Personalised dose management, 6120
- Personalised healthcare, 330
- Personalised medicine, 3
- Personalised therapy, 236
- Pertuzumab, 9119
- PET, 55, 57, 235, 2106, 2107, 5043, 8745, 9431
- PET/CT, 1407, 2103, 2105, 9048, 9329
- PF-02341066, 9084
- PG-11047, 4132
- PGC-1alpha, 9409
- Phantom study, 2017
- Pharmaceutical care, 135
- Pharmaceutical company, 1315
- Pharmacodynamic biomarkers, 4105
- Pharmacodynamics, 420
- Pharmacoeconomics, 3603, 3606, 3615, 3635, 9113
- Pharmacogenetics, 4106, 4109
- Pharmacogenomics, 6099
- Pharmacokinetics, 1204, 1208, 1243, 1250, 3012, 4111, 4113, 5066, 6560, 9233
- Pharmacokinetics/pharmacodynamics, 1201
- Pharmacological cancer treatment, 4269
- Pharmacology, 4137
- Pharmacometrics, 125, 126
- Phase 0 studies, 420
- Phase I/II trials, 421
- Phase I/II trials, drug-metabolizing enzymes, 3531
- Phase I trials, 420, 1202, 1205, 1207, 1209, 1210, 1216, 1230, 1234, 1236, 1238, 1245, 1246, 1247, 1248, 1252, 1255, 1256, 1258, 1260, 1304, 9013, 9120, 9320
- Phase I trials, in healthy volunteers, 1215
- Phase Ib trial, 6587
- Phase II trials, 163, 1306, 6005, 6104, 6121, 6504, 6568, 8587, 8702
- Phase III trials, 157, 158, 6075, 6106, 6505, 6570, 8029, 9318
- Phase III trials, dose selection, 6588
- Phellinus linteus*, 1031

- Phenomenology, 7041
 Phenotype, 9241
 Phosphatase and tensin homolog (PTEN), 5083, 8756
 Phosphatase and tensin homolog (PTEN) loss, 387, 1155
 Phosphatidylinositol-3 kinase (PI3K), 1032, 9012, 9236
 Phosphatidylinositol-3 kinase (PI3K) delta, 1200
 Phosphatidylinositol-3 kinase (PI3K) signalling pathway, 387, 1248, 4105, 5003
 Phospho-EGFR, 1154
 Phospho-HER2, 1154
 Phospho-proteins, 9205
 Photochemical internalization, 107
 Photodynamic, 8584
 Photodynamic diagnostic, 9334
 Photodynamic therapy, 2508
 Photosensitizers, 107
 PHP-melphalan, 6621
 Physical Activity, 4252, 5190
 Physical exercise, 3019
 Physical health, 3019
 Physiotherapy, 264
 PIAS1, 268
 Picline, 4162
 Picture drawing refusal in Mini-Mac scale, 3027
 PIK3CA mutations, 387
 Piper Fatigue Scale, 3076
 PITX2 methylation, 1435
 Planning target volume, 2063
 Plasma VEGF, 804
 Plasma VEGFA, 1415
 Plasmablastic lymphoma, 9218
 Platinum, 1129
 Platinum resistance, 8036
 Pleural effusion, 344, 2101, 2158
 Pleural malignant mesothelioma, 9054
 Pleurodesis, 344, 2101
 Pleuroscopy, 2158
 Podoplanin, 8520
 Poly(ADP-ribose) polymerase, 247
 Polyamine analogue, 4132
 Polycomb, 1003
 Polycythemia vera, 9210
 Polyglutamic acid, 25
 Polymeric nanoparticles, 28
 Polymorphisms, 1040, 1137, 4115, 6125, 6158, 6639, 7155, 8518, 9425
 Polyp, 6154
 Polyphenolic compounds, 9326
 Polyprenol, 1013
 Poor prognosis, 9418
 Poor prognosis patients, 9231
 Poor quality of life, 8608
 Population approach, 126
 Population-based study, 3501
 Population pharmacokinetics, 123
 Portal vein resection, 2513
 Position verification, 280
 Post-induction bevacizumab exposure, 9090
 Post-mastectomy radiotherapy, 5128
 Post-progression bevacizumab exposure, 6013
 Post-progression EGFR therapy, 6143
 Post-progression survival, 9111
 Post-traumatic growth, 1085
 Postoperative morbidity, 6072
 Postoperative mortality, 6069
 Postoperative radiation, 8572
 Postprostatectomy, 7027
 Power, 421
 PPAR-gamma, 1047, 1238, 9059, 9207
 Practice patterns, 6616, 6618, 6620, 9401
 Preclinical models, 276, 1161
 Preclinical studies, 9303
 PREDICT Consortium, 246
 Predicting value, 1425
 Prediction of outcome, 1414
 Prediction of response, 5170
 Prediction of survival, 4234
 Predictive and prognostic biomarker, 6130
 Predictive assay, 1420
 Predictive biomarkers, 1149, 1430, 6137, 9009
 Predictive biomarkers, development, 1144
 Predictive factors, 92, 1005, 1404, 5080, 6099, 7050, 7154, 9400, 9406
 Predictive markers, 1106, 5173, 5175, 7160, 8594
 Predictive models, 3015, 6045, 7006, 7007
 Predictor of recurrence, 7005
 Predictors, 39
 Prednisone, 9200
 Preference of patients for therapy, 3632
 Pregnancy, 9433
 PREMM1,2 model, 6035
 Preoperative assessment, 4168, 6545
 Preoperative chemoradiation, 6527
 Preoperative chemotherapy, 6502
 Preoperative radiotherapy, 6055
 Preoperative risk assessment, 6070
 Preoperative treatments, 6018
 Preoperative visit, 4190
 Prevalence, 3520
 Prevention, 4238
 Primary brain tumors, 3524
 Primary breast cancer, 3615
 Primary cancer, 3520
 Primary cervical cancer, 8015
 Primary hepatocarcinoma, 6537
 Primary liver cancer, 6536
 Primary tumour, 398
 Priority criteria, 3624
 Probiotic bacteria, 77
 Procedural pain, 3058
 Procedural volume, 3616
 Professional reintegration, 4250
 Prognosis, 39, 304, 1035, 1072, 1132, 1146, 1452, 5011, 5012, 5039, 5107, 5182, 5198, 6145, 6606, 6631, 6635, 6636, 7019, 7166, 7172, 8044, 8504, 9030, 9214, 9235, 9405
 Prognostic biomarker, 1445
 Prognostic factors, 1090, 1150, 4110, 5032, 5047, 5094, 5098, 5120, 5149, 6513, 6558, 6603, 7049, 7150, 7161, 7167, 8024, 8038, 8606, 9063, 9321, 9436, 9437
 Prognostic factors for survival, 8740
 Prognostic markers, 144, 1310, 9333
 Prognostic or predictive biomarkers, 1447
 Prognostic score, 3621
 Prognostic value, 1152, 6052
 Prognostication and staging, 6633
 Programme implementation, 54
 Progression-free survival (PFS), 156, 164, 1301, 9016
 Proliferation, 5011, 5170
 Prolyl hydroxylases, 1037
 Promoter hypermethylation, 1038
 Promoter methylation, 6026
 Promyelocytic leukaemia, 9217
 Prone position, 5121
 Prophylactic mastectomy, 3532

- Prophylactic salpingo-oophorectomy, 3532
 Prophylaxis, 3533
 Prosopis cineraria, 9326
 Prospective longitudinal study, 3037
 Prospective study, 5179
 Prostate, 1163, 1430, 7022, 7023, 7033
 Prostate brachytherapy, 285
 Prostate cancer, 141, 209, 210, 211, 244, 245, 259, 262, 1103, 1124, 1413, 1426, 2015, 2016, 2018, 2032, 2033, 2038, 2060, 2159, 3038, 3520, 3608, 3609, 3631, 4013, 4034, 4163, 4187, 6565, 7000, 7002, 7005, 7006, 7007, 7009, 7010, 7012, 7017, 7018, 7019, 7024, 7025, 7026, 7028, 7029, 7032, 7034, 7035, 7036, 7039, 7040, 7041, 7042, 7043, 7044, 7051, 7052, 7054, 7062, 7063, 7101, 7102
 Prostate cancer immunotherapy, 7011
 Prostate cancer staging, 7063
 Prostate-specific antigen, 7100
 Prostate stem cell antigen (PSCA), 6591
 Prosthesis, 8583
 Protease activated factors, 1126
 Proteasome, 1079, 1133
 Proteasome inhibitor, 1210, 6507
 Protein C, 9210
 Protein intake, 3510
 Protein kinase C delta, 8714
 Protein kinase inhibitors, 1059, 7037
 Proteomics, 139, 347, 1135, 1430, 5082
 Protocol, 137
 Proton and ion beams, 282
 Proton beam therapy, 8723
 Proton radiotherapy, 2040, 8517
 Protons, 7024
 Pruritus, 3068
 Pseudomyxoma peritonei, 31, 2508
 pSTATs, 5108
 Psycho-oncology, 1085, 3081, 3536, 3641, 3645, 8592
 Psychogenic reactions, 5140
 Psychological adjustment, 9065
 Psychological and social reaction, 193
 Psychological distress, 1453, 8605
 Psychological intervention, 4199
 Psychometric validation, 4224
 Psychosexual guidance, 6042
 Psychosocial aspects, 5188
 Psychosocial effect, 9243
 Psychosocial experiences, 4167
 Psychosocial support, 3070, 3641, 4166, 4196
 Pterocarpanquinone-LQB-118, 1213
 Publishing standards, 1314
 Pulsed X-ray radiation, 2031
 Pyrosequencing, 1421
 8q24 region, 6153
 QLQ-C30, 3628
 QTc, 7056
 Quadrantectomy, 2504
 Qualitative methodology, 4211
 Qualitative research, 49, 4150, 4198, 4263, 6619
 Quality assessment, 5035, 8025
 Quality assurance, 136, 137, 2024
 Quality assurance guidelines, 54
 Quality indicators, 3630, 3638, 5035
 Quality of cancer care, 3025
 Quality of care, 3622, 6001
 Quality of life, 24, 50, 78, 135, 360, 1091, 3004, 3005, 3006, 3023, 3029, 3031, 3032, 3033, 3034, 3038, 3040, 3041, 3064, 3614, 3628, 3645, 4151, 4160, 4161, 4200, 4201, 4246, 4248, 5086, 5119, 5122, 5163, 5184, 5200, 6017, 6071, 6112, 6148, 6159, 6599, 7029, 7042, 7168, 8592, 8605, 8607, 8715, 8738, 9070, 9076, 9091, 9312
 Quality of oncology practice, 184
 Quality of surgery, 6000
 Questionnaires, 3040, 4224
 RAD001 (everolimus), 5005, 6560, 6561, 6566, 6571, 6572, 6573, 6581, 6585, 6626, 6628, 8502
 Radiation, 7, 36, 60, 73, 206, 1056, 1129, 1160, 5126, 6525, 8730
 Radiation-associated sarcoma, 9417
 Radiation enteritis, 2042
 Radiation-induced biochemical alterations, 1164
 Radiation-induced cancer, 7122
 Radiation-induced fibrosis, 1136
 Radiation-induced intestinal toxicity, 2004
 Radiation-induced liver disease, 405
 Radiation-induced oxidative stress, 2023
 Radiation oncology, 208, 234
 Radiation pneumonitis, 9046, 9050
 Radiation proctitis, 2032, 2033
 Radiation sensitivity, 81
 Radiation therapy, 148, 282, 4100, 6542, 8534, 8729, 9029, 9041
 Radiation to bone, 3061
 Radical cystectomy, 212
 Radical mastectomy, 5037
 Radical prostatectomy, 211
 Radical surgery, 1441, 9027
 Radio-dermatitis, 8562
 Radio-induced cell death, 1018
 Radiobiology of APBI, 364
 Radiochemotherapy, 8537, 8590
 Radioenhancement, 2001
 Radiofrequency ablation, 6010, 6011, 8582
 Radiofrequency ablation + 3DRT, 9038
 Radiograph, 9064
 Radiological disaster, 3641
 Radionuclide therapy, 6101
 Radiopeptide, 6605
 Radioresistance, 418
 Radiosensitisation, 1045, 1165, 6031
 Radiosensitised treatment, 5089, 9328
 Radiosensitisers, 82, 2020, 2152, 4014, 6540, 9429
 Radiosurgery, 2053, 4012, 8700, 8726, 8731, 8734, 8739, 8740
 Radiotherapy, 6, 8, 106, 111, 113, 137, 149, 209, 257, 269, 271, 307, 316, 320, 339, 365, 367, 391, 393, 414, 1045, 1083, 1088, 1407, 2010, 2011, 2019, 2021, 2024, 2033, 2035, 2036, 2037, 2045, 2052, 2152, 3010, 3022, 3027, 3033, 3624, 4170, 4264, 4268, 5020, 5036, 5037, 5118, 5124, 5127, 5129, 6002, 6530, 6532, 6539, 6543, 7005, 7006, 7007, 7010, 7020, 7024, 7025, 7026, 7027, 7028, 7033, 7035, 7036, 7039, 7062, 7127, 8012, 8015, 8016, 8017, 8020, 8021, 8023, 8507, 8509, 8512, 8515, 8516, 8518, 8531, 8551, 8558, 8559, 8566, 8569, 8570, 8571, 8597, 8705, 8719, 8732, 8733, 9034, 9040, 9042, 9047, 9070, 9218, 9220, 9223, 9416, 9417
 Radiotherapy accelerator, 280
 Radiotherapy alone, 8508
 Radiotherapy and chemotherapy, 4165
 Radiotherapy planning, 2018
 Radiotherapy technique, 8573
 Radium-223, 7008
 RAF inhibition, 130
 RAF inhibitor, 300
 Raman spectroscopy, 9327
 Ramp-up, 6582

- Randomised controlled trials, 4173, 5026, 7003
 Randomised controlled trials/methods, 1314
 Randomised trials, 1225, 3005, 5159, 6006, 6513, 8512
 RANK ligand, 7003
 RapidArc, 2049, 2068, 2069, 8575
 Rare cancer, 1206, 6619
 Rare cell analysis, 203
 Rare circulating tumour cells, 205
 Rare tumours, 105
 RAS, 384
 RASSF1A, 8505
 Rb level, 1030
 RBE, 2029
 RCAS1, 1075
 Re-challenge, 7050
 Re-irradiation, 5033, 8563, 8725
 Reactive oxygen species, 1021, 1048
 Receptor tyrosine kinase inhibition, 6609
 Receptor tyrosine kinase inhibitor intolerance, 7147
 RECIST criteria, 1147, 1401
 Recombinant albumin-fusion technology, 1216
 Recommendations, 225
 Recommended dose, 1250
 Reconstruction, 6079
 Recovery, 4259
 Rectal bleeding, 7031
 Rectal cancer, 218, 250, 251, 252, 253, 320, 1035, 2511, 4000, 4252, 6000, 6002, 6018, 6031, 6033, 6038, 6042, 6044, 6047, 6049, 6050, 6052, 6053, 6054, 6056, 6059, 6060, 6071, 6126, 6130
 Rectal gastrointestinal stromal tumour, 9419
 Rectal neoplasm/radiotherapy, 6057
 Recurrence, 1098, 5128, 6514, 6518, 8747
 Recurrent and metastatic disease, 8589
 Recurrent breast cancer, 5033
 Recurrent malignant glioma, 8702, 8749, 8750, 8752
 Recurrent rectal cancer, 6008
 Referral, 9064
 Refractory metastatic colon cancer, 6144
 Refractory paediatric-type sarcoma, 9422
 Regional chemotherapy, 2507, 9423
 Regional node dissection, 46
 Regional perfusion, 2506
 Regional therapy, 9304
 Register study, 1303
 Regorafenib, 1236, 6576, 7141
 Regulation pattern, 8707
 Regulatory agency, 1315
 Regulatory approvals, 1309
 Regulatory T cells (Treg), 1096, 1111, 1416, 9209, 9215
 Regulatory T lymphocytes, 9131
 Rehabilitation, 264, 4250, 4257, 4261, 6637
 Reintegration, 6017
 Relapse, 6125, 8003
 Relapsed head and neck cancer, 8592
 Relative care, 4188
 Relaxation, 4241
 Relieving anxiety, 4209
 Religious observance, 4256
 REMARK recommendations, 1310
 Renal cancer, 7114, 7135
 Renal cancer drugs, 69
 Renal cell cancer, 213, 7109
 Renal cell carcinoma, 70, 71, 72, 309, 1141, 1444, 3006, 7103, 7115, 7116, 7131, 7140, 7141, 7151, 7153, 7155, 7156, 7161, 7163, 7164, 7165
 Renal cell carcinoma (RCC), 1444, 7165
 Renal safety, 3060
 Renal tumours, 4103
 Reporting of adverse events, 4266
 Reproduction, 151
 Resectable gastric cancer, 6515
 Resistance, 7113, 9111
 Resource utilisation, 6616, 6618, 6620
 Response assessment, 57
 Response evaluation, 6115, 8578
 Response shift, 3042
 Response to anthracycline-based chemotherapy, 5174
 Response to therapy, 1143
 Retinoblastoma, 2058, 4104
 Retroperitoneal sarcomas, 306, 307
 Retrospective analysis, 7131
 Return to work, after breast cancer diagnosis, 263
 Return to work, after breast cancer surgery, 5183
 Rhabdomyosarcoma, 101, 1240, 9430
 Ribonucleotide reductase, 9217
 Right colectomy, 6081
 Right-sided colon cancer, 6081
 Rilotumumab, 6504
 Risk, 3626, 8521, 9308
 Risk estimation, 3507
 Risk factors, 3516, 6127, 8591, 8599, 9082
 Risk factors for thrombosis, 3077
 Risk of pancreatic cancer, 6613
 Risk prediction, 7100
 Risk score, 5044
 Rituximab, 1302, 1305
 RNA, 15
 RNA binding proteins, 12
 RNA interference, 246
 RNA interference machinery, 1100
 Robotic-assisted laparoscopic prostatectomy, 7041
 Robotic radiosurgery, 8737
 Robotic stereotactic radiosurgery, 2053, 8734
 Robotic stereotactic radiotherapy, 4124
 Robotic surgery, 38, 4230
 ROMA, 8036
 RON, 6027
 RON (MST1R), 6609
 ROS, 1
 Rosiglitazone, 2004
 Round robin, 9002
 RT-PCR, 1020, 4108, 9062
 Rural patients, 3619
 S-1, 5164, 6118, 6521, 6532, 6578, 6586, 6595, 6596, 8015, 8546, 9094
 S-1 and bevacizumab, 6121
 19S activator, 1079
 Sacrum insufficiency fractures, 2057
 Safety, 38, 8004, 8032, 8744, 9096, 9129
 Safety culture, 4225
 Safety promotion, 1315
 Salivary duct carcinoma (SDC), 8572
 Salivary gland, 40
 Salivary gland function, 1083, 4133
 Salvage chemotherapy, 7166
 Salvage radiotherapy, 7009
 Salvage therapy, 144, 7020, 9075, 9085
 Same-sex couples, 152
 SAMITALS® framework, 3067
 Saracatinib, 1252
 Sarcoma, 306, 337, 338, 2506, 9402, 9403, 9420, 9422, 9424
 Sarcoma patients, 9412

- Sarcoma treatment, 9400
 Sarcomatoid mesothelioma, 9146
 SB202190, 1029
 Scalp cooling, 3009, 3050, 3054, 4242
 Scalp skin metastases, 3009
 Scientific publications, writing/reviewing, 358
 Screening, 224, 1221, 2107, 3514, 3522, 3534, 3538, 3539, 8010
 Screening tools, 312, 4032
 SDF-1 α , 6512
 Second-line chemotherapy, 6103, 7016
 Second-line therapy, 6568
 Second-line treatment, 6111, 7143, 7153, 9121
 Second malignant neoplasm, 4116
 Secondary drug exposure, 3629
 Secretion ability of cytokines, 1111
 Selective chemotherapy, 9435
 Self-adjuvanted mRNA, 1253, 7046
 Self-esteem, 4207
 Self management, 4259
 Self-report, 360
 Self-reported outcome, 3043
 Semantic interoperability, 2161
 Semi-mechanistic PK/PD models, 126
 Seminoma, 7108
 Seminoma stage I, 7122
 Semuloparin, 3075
 Senescence, 1002, 1003
 Sense of coherence, 3037
 Sentinel lymph node, 318, 1416, 5040, 5145, 5146
 Sentinel lymph node biopsy, 46, 9302
 Sentinel lymph node dissection, 5139
 Sentinel lymph node procedure, 5009
 Sentinel node, 5014, 5131, 5152, 9301, 9316
 Sequencing, 5122
 Sequential chemoradiotherapy, 8547, 9047
 Sequential targeted therapies, 7149
 Sequential therapy, 1303, 7131, 7152
 Seroma, 2512
 Serum albumin, 1457
 Serum and tumor samples, 9136
 Serum DNA, 1148
 Service, rural vs urban patients, 3619
 Service improvement, 4152
 Sexual (dys)function, 6042
 Sexuality, 3031, 4169
 sFLT-1, 1112
 Shared care, 368
 Sharing data, 349
 Shear stress, 1165
 Shift of care, 4228
 Short-course radiotherapy, 4118
 shRNA screen, 122
 Side effects, 7028
 Side effects of cancer treatments, 405, 4198, 4253
 14-3-3 sigma, 1120
 Signal transduction, 1070
 Signal transduction pathways, 1052
 Signalling pathways, 1450
 SiHa cell line, 1033
 Simultaneous integrated boost (SIB) approach, 8515, 8565
 Single arc, 2047
 Single-cell analysis, 203
 Single-cell network profiling, 1144
 Single chain fragment variable, 1239
 Single nucleotide polymorphism (SNP), 1405, 1423, 1432, 6025, 7115, 7156, 8521
 Single vocal cord, 8559
 Sinonasal cancer, 8560
 Sinonasal tumours, 8554
 Sinusoidal injury, 6156
 Sipuleucel-T, 7002, 7012
 Sirolimus, 9420
 Sirtuins, 6510
 Skeletal muscle wasting, 9137
 Skeletal-related events, 3044, 3613, 9148
 Skin carcinogenesis, 9311
 Skin carcinoma, 9300
 Skin care, 4268
 Skin reactions, 4268
 Skin-sparing mastectomy, 5141, 5142
 Skip mediastinal nodal metastases, 9055
 Skip-N2 metastases, 9055
 Sleep disorders, 4253
 Sleep-wake disturbances, 4272
 Small bowel adenocarcinoma, 6603
 Small bowel injury, 6057
 Small breast tumours, 5166
 Small cell lung cancer, 3034, 9036, 9049, 9102, 9103, 9104, 9125
 Small cell lung carcinoma, 9140
 Small-molecule kinase inhibitor, 1251
 Small molecule screening, 1220
 Small tumour, 5187
 Smoking, 3517, 8500, 8503
 Snail1, 1053
 Social life, 50
 Social network, 4261
 Social support, 51, 4159, 4205, 4260
 Socio-economic status, 8716
 Sodium butyrate, 8757
 Soft tissue sarcomas, 101, 339, 2001, 9401, 9416, 9418, 9429, 9432
 Soft-tissue tumours, 340
 Software for data management, 2160
 Solid tumours, 1209, 1230, 1243, 1244, 3071
 Solitary nodules, 2108
 Somatic mutation, 143, 1427
 Somatostatin analogs, 3003, 9097
 Sorafenib, 1056, 1247, 5026, 6091, 6500, 6582, 7151
 SOX8, 8704
 Sox2 high-mobility group, 1220
 SPARC, 1068
 Specialist nurse functions, 4181, 4188, 4247
 Specimen radiography, 5150
 Spermatozoa, 151
 Sphingolipid, 1163
 Sphingosine kinase 1, 1104
 Spinal metastasis, 2011
 Spinner, 363
 Splenic artery, 6556
 Splenomegaly, 9223
 Splicing, 1041
 Spot scanning, 8723
 Spouses, 4210
 Squamous cell carcinoma (SCC), 130, 8527, 8528, 8536
 Squamous cell carcinoma (SCC) of head and neck (SCCHN), 388, 8501, 8511, 8536, 8546, 8570, 8585, 8607
 Src inhibitor, 1252
 Stability, 1305, 1313, 1318
 Stage, 6627
 Stage I seminoma, 7168
 Stage II colon cancer, 1411, 6102
 Stage III-N2 NSCLC, 67
 Stage IIIA-N2 NSCLC, 9035

- Stage IIIC breast carcinoma, 5091
 Staging, 6524, 8527
 Staging systems, 8023
 Staging–restaging, 66
 Starvation, 166
 Stat3, 1025, 1056, 8042
 Stat3 and NF- κ B, 7018
 Static-field intensity-modulated radiation therapy, 2046
 Statistical analysis, 2037
 Statistical methods, 358
 Stem cell therapy, 6
 Stem cell transplantation, 4154
 Stem cells, 40, 160
 Stenting, 6087
 Stereotactic body radiotherapy (SBRT), 17, 403, 2011, 2044, 2057, 2063, 2066, 4002, 6056, 6534, 9010, 9045, 9053
 Stereotactic radiosurgery, 8725, 8736
 Stereotactic radiotherapy, 406, 8722, 8724
 Stereotaxy, 8730, 8737
 Steroid, 2003
 Steroid hormones, 5074
 Steroid receptors, 1057
 Steroid sulphatase inhibitor, 7047
 Stomach, 9232
 Stomach cancer, 6622
 Stroma, 6082
 Stromal fibroblasts, 2165
 Strontium chloride-89, 2043
 Suboptimal patients, 6593
 Sun exposure, 4269
 Sunitinib, 1006, 1138, 1139, 1140, 1141, 1301, 1444, 3036, 4018, 6517, 6569, 7061, 7106, 7134, 7139, 7154, 7160, 7165, 9421
 Sunitinib and buccodental toxicities, 7145
 Sunitinib or sorafenib treatment, 7132
 Sunitinib-related toxicity, 9425
 Sunitinib resistance, 7143
 Superficial bladder cancer, 7128
 Support, 265, 3070
 Support needs, 4229
 Supportive care, 3045, 4164, 4165, 4237, 4246, 4262
 Supportive care needs, 4232
 Suppressor cell, 9130
 Supraclavicular recurrence, 5041
 Surfactant, 6129
 Surgeon specialty, 3616
 Surgery, 33, 47, 70, 153, 191, 208, 216, 237, 252, 290, 296, 306, 337, 413, 2510, 2515, 5129, 5138, 5140, 5147, 5148, 6062, 6067, 6555, 7129, 8719, 9419
 Surgery and chemotherapy, 6040
 Surgical and pathological quality, 6502
 Surgical quality, 6503
 Surgical radicality, 9415
 Surgical resection, 6549, 6553, 8728, 8732, 9071
 Surgical stress, 1012
 Surgical technique, 6012, 6548
 Surrogate endpoints, 158, 3607
 Surveillance, 7108, 7123
 Surveillance system, 4275
 Survival, 223, 320, 1000, 3066, 3501, 3502, 3512, 5040, 5094, 5132, 6013, 6157, 6547, 6556, 6617, 6623, 7038, 8031, 8033, 8049, 9020, 9031, 9073, 9081, 9090, 9202, 9241, 9302, 9325
 Survival analysis, 6615
 Survival and PFS, 9227
 Survival impact, 8750
 Survival outcomes, 7136
 Survival rate, 3526
 Survival study, 8755
 Survival times, 9077
 Survival trends, 3022
 Survivin, 2030
 Survivors, 23, 24
 Survivorship, 146, 265, 370, 3028, 3052, 4016, 4249, 4255, 5186
 Suspension of azacytidine, stability, 1318
 SUV max, 1408
 Symptom assessment, 309, 3041, 4180
 Symptom burden, 5088
 Symptom clusters, 4263
 Symptom distress, 3033
 Symptom management, 115, 310, 3637, 4176, 4270, 4274
 Symptoms, 39, 3004, 4194, 4240, 4271, 5200
 Symptoms and side effects, 361
 Synchronous liver metastasis, 6080
 Synergism, 1222
 Synthetic cannabinoids, 1237
 Synthetic lethality, 1221
 Systemic access barriers, 4256
 Systemic chemotherapy, 6603, 8590
 Systemic therapy, 5165, 6128, 6563, 7109, 9152, 9433
 Systemic treatment, 316, 415, 6016, 9147
 Systemic treatment, neuroendocrine tumours, 6598
 Systems biology, 3
 T-cell lymphoblastic lymphoma-leukaemia, 9241
 T cell responses, 7011
 T cells, 59
 T4 colon cancer, 6116
 T1 G3 tumours, 7128
 T lymphocytes, 35
 T regulatory cells, 9322
 TAC chemotherapy, 5167
 Tailored treatments, 251
 TAK-700, 7014
 Tamoxifen, 1065, 1159, 5016, 5163, 5171, 8714
 Tamoxifen metabolism, 1405
 Tandem mass spectrometry, 138
 Target delineation, 2017
 Target movement, 2002
 Target volume, 234
 Target volume definition, 2014
 Targeted agents, 82, 393, 400, 801, 1206, 1309
 Targeted therapy, 87, 128, 148, 178, 187, 199, 262, 292, 338, 373, 379, 394, 800, 1029, 1061, 1095, 1114, 1167, 1226, 1235, 3071, 3635, 7157, 7158, 7163, 8533, 8588, 9044
 Targeting, 5, 1231, 1240
 TargetPrint, 5189
 Targets for therapy, 222
 TAS-102, 6005, 6099
 Tau-1, 5080
 Taxanes, 5051, 5079
 Teamworking assessment, 4153
 Techniques & dosages in Hodgkin's lymphoma, 2052
 Technology, 38, 4264
 Teenage and young adult cancer, 3512
 Teenagers, 3070, 4194, 4206, 5109
 Teenagers and young adults, 51, 4261
 Tele pathology, 2164
 Telehealth, 10, 4180
 Teleoncology, 2155
 Telephone follow-up, 4178, 4187, 4247
 Telmisartan, 1261
 Telomerase, 1008
 Telomerase inhibition, 9204

- Temozolomide, 4117, 8742, 8743, 8744, 8745, 9319
 Temozolomide and bevacizumab, 8741
 Temsirolimus, 6105, 6604
 Terminally ill cancer patients, 3021, 4234
 Testicular cancer, 146, 214, 7111, 7112, 7123, 7130, 7142, 7168, 7171
 Testicular carcinoma, 7120, 7125
 Testosterone, 5074, 7112
 Text messaging, 2154
 TGF- β , 1023
 TGF- β 1, 1024, 1073
 Thematic synthesis, 4211
 Therapeutic antibody, 1161
 Therapeutic management, 5056
 Therapeutic resistance, 1115
 Therapy, 4136, 8708, 9408
 Therapy of unknown primary cancer, 1259
 Therapy response, 62
 Therapy trials, 266
 Thermoplastic shell, 8519
 Thiopurine-S-methyl transferase, 4115
 Third-line chemotherapy, 5047, 7144
 Thoracoscopic internal mammary lymph node dissection, 5039
 Three-dimensional image guided PDR brachytherapy, 8001
 Three-dimensional imaging, 2018
 Three-dimensional imaging navigation, 2501
 Three-dimensional volumetric planning, 8018
 Thrombocytosis, 3525
 Thromboembolic complications, 9140
 Thromboembolism, 3525
 Thrombosis, 3075, 3530, 9210
 Thrombotic mediators, 1123
 Thymidine kinase, 1454
 Thymidine kinase 1 activity, 1462
 Thymidylate synthetase, 9133
 Thyroid cancer, 1127, 2108, 3507, 3526, 8580, 8584
 TIE2-expressing myeloid (TEM) cells, 6142
 Tight junction, 6506
 Time and motion, 3625
 Time factor, 6052
 Time to disease-related pain, 7002
 Tissue array, 5028
 Tissue Doppler imaging, 1261
 Tissue factor, 1126
 Tissue microarrays, 1075, 1446, 9061
 TLR4, 5106
 T790M mutation, 9017
 TNM staging, 6558, 8601
 Tobacco, 5109, 5181, 9026
 Tobacco carcinogens, 3527
 Tomotherapy, 9047
 Tonsillar carcinoma, 8573
 Toolkit for teamworking assessment, 4153
 Topoisomerase II α , 1448, 5174
 Topoisomerase inhibitors, 6590, 9105, 9422
 Total body irradiation, 4119
 Total lesion glycolysis (TLG), 2041
 Total mesorectal excision, 6033
 Total perineal reconstruction, 6083
 Total skin electron irradiation (TSEI), 9315
 Total thyroidectomy, 8580
 Totally implanted vascular access device, 3023
 Touch pad, 4220
 Toxicity, 394, 1040, 1232, 1309, 2032, 2036, 2037, 4115, 5162, 6528, 7038, 7139, 8529, 8532, 8587, 9042
 Toxicity prediction, 2034
 Toxicity profile, 5154
 TP, 5080
 TP53 gene, 1128
 TPF induction chemotherapy, 8548
 tPSA, 1433
 Trabectedin, 8004, 8031, 8050
 Trachelectomy, 298, 8027
 Tract metastases, 9054
 TRAIL, 1027
 Training and education, 4176
 Trajectories of quality of life, 4160
 Transanal endoscopic microsurgery, 6038
 Transanal pullthrough, 6043
 Transarterial chemoembolization, 6542
 Transcription, 14
 Transcription factor, 1067
 Transcription factor inhibitor, 1220
 Transfection, 1214
 Transition, 409
 Transition from paediatric to adult care, 22
 Transitional cell carcinoma, 7117, 7124
 Translation, 3040
 Transplantation, 291
 Trastuzumab, 1092, 3032, 5000, 5027, 5045, 5065, 5076, 5083, 5093, 5153, 5160
 Trastuzumab emtansine, 5001
 Traumatic lumbar punctures, 4128
 Treatment, 218, 3037, 3610, 4112, 5111, 5168, 6108, 6501, 6626, 7114, 9005, 9057, 9231
 Treatment, for progression with effective EGFR-TKI therapy, 9118
 Treatment, management, 9421
 Treatment, modifications, 7133, 7136, 7162
 Treatment, monitoring, 1316
 Treatment, planning, 56, 252
 Treatment, prognosis, 5031
 Treatment approach, 4000
 Treatment compliance, 8547
 Treatment decision, 4033
 Treatment options in recurrent malignant glioma, 8752
 Treatment outcome, 9219, 9412
 Treatment paradigm, 310
 Treatment patterns, 3504, 9114, 9331
 Treatment response, 9081
 Treatment results, 8052
 Treatment time, 2064
 Treatment tolerance, 217
 Trials, methodology, 86, 1300
 Triapine, 6525
 Tricellulin, 6506
 Trichometer, 4227
 Trifunctional antibody, 6515
 Trimodality therapy, 9032
 Triple-negative breast cancer, 1166, 3502, 3516, 3528, 5025, 5029, 5048, 5052, 5054, 5073, 5094, 5099, 5132, 5178, 5199
 Triplet chemotherapy, 6096, 6111
 Tropism, 416
 TS, 5080
 TSU-68, 1208, 5058
 Tumour burden, 6022
 Tumour cells, 6076
 Tumour characteristics, 5114
 Tumour diameter, 8052, 9430
 Tumour growth, 1012, 1095
 Tumour growth model, 2031
 Tumour immunology, 1080
 Tumour kinetics, 6115
 Tumour margin assessment, 2151

- Tumour markers, 1411
 Tumour microenvironment, 134, 1064
 Tumour microenvironment and modification, 1164
 Tumour progression, 1306
 Tumour size, 5193
 Tumour stroma ratio, 5132
 Tumour suppressor, 229, 1084
 Tumour targeting, 28, 1219
 Tumour tissue culture, 8598
 Tumour volume, 9430
 Tumourgraft, 1149
TWIST1 gene, 5012
 Two-arm randomized study, 9427
 Two-week-wait rule, 6066, 9031
 Type C coping style, 2021
 Tyrosine kinase, 1086
 Tyrosine kinase activity profiling, 1419
 Tyrosine kinase inhibitor, 301, 9092
 Tyrosine kinase microarrays, 141
- Ubiquitin, 1060
 Ubiquitin proteasome system, 9137
 UFT/gemcitabine, 9095
 UFT/leucovorin, 6119
 Ultradilution, 1011
 Ultrafractionated radiotherapy, 8701
 Ultrasound, 5123, 5137
 Ultrasound-guided FNAC, 9301
 Unbounded body, 4158
 Undernutrition, 3046
 Undetected radiographic abnormalities, 9064
 Uniparental disomy, 1050
 Unknown primary, 8552
 Unresectable or recurrent colorectal cancer, 6121
 Upper gastrointestinal cancer, 6637
 Upper urinary tract, 7124
 Upstaging, 318
 Urinary bladder cancer, 7117
 Urinary diversion, 212
 Urothelial cancer, 7106, 7144, 7157, 7167
 Urothelial carcinoma, 7107
 Urothelial cell cancer, 7118
 User involvement, 4152
 Uterine cervical cancer, 2048, 8012, 8017
 Uterine cervical carcinoma, 8043
 Uterine leiomyosarcoma, 8026
- Vaccination, 53
 Vaccine therapy, 8039
 Vaccines, 60, 1203
 Vadimezan, 1116
 Vaginal melanoma, 9330
 Vaginal vault, 8019
 Validity of Swedish Piper Fatigue Scale, 3076
 Variability of volume delineation, 1147
 Vascular disrupting agents, 1087, 1160
 Vascular endothelial growth factor-A (VEGF-A), 1112
 Vascular endothelial growth factor (VEGF), 75, 378, 1423, 8593, 9408
 Vascular endothelial growth factor (VEGF) genotyping, 6612
 Vascular endothelial growth factor (VEGF) polymorphisms, 7103
 Vascular endothelial growth factor (VEGF) receptors, 6134, 6139, 6573, 7132, 9216
 Vascular endothelial growth factor (VEGF) signaling pathway, 1097
 Vascularity, 2102
 Vasculogenesis, 73
 Vasohibin, 1063
 Vector, 6155
- Vectorized radiotherapy, 9303
 Vemurafenib, 300, 330
 Venous thromboembolism, 1102, 3001, 3002, 3077
 Venous thrombosis, 3530
 Venous thrombotic event (VTE), 3053
 Vertical rectus abdominis myocutaneous flap, 6083
 Vesicants, 4189
 Video conference, 2164
 Video-linked medical oncology clinics, 2155
 Views on palliative care, 4239
 Vinblastine, 9319
 Vinorelbine, 5076, 9094
 Virotherapy, 9323
 Virus, 8708
 Viscum album L versus etoposide, 9427
 Vitamin D, 3521, 5107
 Vitamin D analogs, 1010
 Vitamin D3 analogs, anticancer activity, 5104
 Vitamin E, 6164
 Voice quality, 8534
 Voice rehabilitation, 8583
 Volume comparison, 6538
 Volume delineation, 1147, 9043
 Volume of initial irradiation, 8729
 Volumetric modulated arc therapy, 2046, 2047, 2050
 Volunteers, 4218
 Vomiting, 3020, 4273
 Vorinostat, 6104, 8711, 9141
 Vulval cancer, 8028
 Vulval intraepithelial neoplasia, 8028
 Vulvar melanoma, 9330
- Waiting time, 3624, 6066
 Warburg theory, 1162
 Web-based real-time analysis, 2163
 Weekly cisplatin chemotherapy, 8512
 Weekly paclitaxel, 8002
 Weight loss, 8516
 WHO classification, 340
 WHO criteria, 6634
 Whole brain radiotherapy, 8706
 Wide local excision, 5150
 Withaferin-A, 1022
 Wnt/ β -catenin signaling, 1031
 Womanliness, 4254
 Women, 5109, 5181
 Woodworker, 8530
 Workforce, 3642, 4181
 Wound drainage, 2512
 WT1 peptide vaccination, 9242
 WT1 tetramer, 9242
- Xelox, 6114
 Xeloxiri, 6110
 Xenograft model, 5085
 Xerostomia, 40
XRCC1 Arg399Gln, 8037
- YB-1, 8042
 Young adults, 8556, 9224
 Young age, 5197, 7172
 Young Italian radiation oncologists, 2070
 Young patients, 9147
 Young people, 49
 Young women, 313, 4258, 8049
- Zoledronic acid, 3044, 3051, 3060, 3602, 3603, 5019, 5022, 5097, 5155, 5157, 5201, 9117, 9202
 Zyxin, 8524